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Pre-eclampsia is a pregnancy specific disorder and a major cause of maternal 
mortality. The pathophysiology of pre-eclampsia is still unknown and it is 
ineffective to identify women who are at high risk of developing the illness. Recent 
evidence suggests that circulatory factors are released from the placenta into the 
maternal circulation, which in turn result in an excessive maternal inflammatory 
response and subsequently generalized vascular endothelial dysfunction. However, 
the key factors have yet to be identified or further verified. 2D-PAGE were 
performed to display the differential proteins from the plasma of established 
pre-eclamptic and control women. Candidate proteins were identified by peptide 
mass fingerprinting and product ion data with the use of MALDI-TOF-TOF-MS. 
The differential plasma levels were confirmed by immunoassays. The concentration 
of H-ficolin and L-ficolin，proteins in the lectin-complement pathway, playing an 
important role in innate immunity, were found to be significantly lower in 
pre-eclamptic plasma. H-ficolin and L-ficolin can be novel serological markers for 
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Chapter 1 Introduction 
Pre-eclampsia is a pregnancy-specific disorder and a major cause of maternal 
mortality. The aetiology of pre-eclampsia is still unknown and there is no effective 
tool to identify women who are at high risk of developing the illness. Recent 
evidence suggests that circulatory factors are released from the placenta into the 
maternal circulation, which in turn result in an excessive maternal inflammatory 
response and subsequently generalized vascular endothelial dysfunction. However, 
the key ones have yet to be identified or further verified. One of the key aims of 
modem antenatal care is to detect pre-eclampsia as early as possible thereby 
allowing appropriate management. Unfortunately, no simple tests are currently 
available to do this and the detection of pre-eclampsia continues to depend upon 
frequent antenatal visits in late pregnancy for blood pressure measurement and 
urinalysis. These approaches are both costly and neither particularly sensitive nor 
specific. Clearly, a sensitive, specific, cheap and non-invasive predictive marker of 
pre-eclampsia would be an important advancement; serological protein marker(s) 
would be ideal. 
Proteins as the functional units that regulate metabolism are good targets for 
identification of the circulatory factors in pre-eclampsia. Proteome analysis is the 
analysis of the entire protein complement expressed by a genome or a cell or a tissue 
type. The proteome is dynamic and changes with time and changes according to 
physiological state. Two-dimensional polyacrylamide gel electrophoresis (2D-
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PAGE) based proteomic analysis involves the systematic separation, identification, 
and quantification of many proteins simultaneously in a single sample. This 
proteome analysis of plasma from pre-eclamptic and control subjects may allow 
identification of plasma protein(s) associated with pre-eclampsia and aiding the 
discovery of disease markers associated with pre-eclampsia. 
There were three objectives in this study. 
1) To identify the differences in protein profiles between the plasma of pre-
eclamptic and non-pre-eclamptic women. 
2) To uncover the protein identities of the differential proteins in association 
with pre-eclampsia. 
3) To validate the findings by measuring the plasma levels of the identified 
proteins in another prospective cohort. 
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Chapter 2 Pre-eclampsia 
Pre-eclampsia is a pregnancy specific disorder. It affects about 5 % of pregnant 
women in the developed world (Vatten & Skjaerven，2004; Hauth et al.，2000) and 
about 2% of pregnant women in Hong Kong (Anonymous, 1999). Pre-eclampsia is 
the second leading cause of maternal mortality, accounting for 12-18% of 
pregnancy-related maternal deaths (Warden, 2005). It is one of the most common 
causes of perinatal morbidity and mortality, resulting in an estimated 35-300 deaths 
per 1000 births depending on neonatal support capabilities of the hospital delivering 
care. This mortality rate is almost double that of normotensive pregnancies (Brooks, 
2005). In severe pre-eclampsia, there are always the maternal and fetal 
complications. The magnitude of risk depends on gestational age at time of 
diagnosis, delivery, severity of disease process, and presence of associated medical 
disorders. Maternal complications include abruptio placenta (1-4%)，disseminated 
coagulopathy/HELLP syndrome (10-20%), pulmonary oedema/aspiration (2-5%), 
acute renal failure (1-5%), eclampsia (1%) and death (rare) (Sibai et al., 2005). The 
fetal complications include preterm delivery (15-67%), fetal growth restriction (10-
25%), hypoxia-neurologic injury (<1%) and perinatal death (1-2%) (Sibai et al., 
2005). 
Pre-eclampsia is diagnosed on the basis of hypertension with proteinuria. 
Hypertension is defined as diastolic blood pressure to at least 110 mmHg on one 
occasion or at least 90 mmHg on two or more occasions at least four hours apart, 
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with the presence of the significant proteinuria in subjects with no history of pre-
existing or chronic hypertension was evident. Significant proteinuria was defined as 
proteinuria higher than 0.3 g/day or at least ++ on dipstick testing in two clean-catch 
midstream urine specimens collected at least four hours apart (International Society 
for the Study of Hypertension in Pregnancy, Davey & MacGillivray，1988). 
The progression of pre-eclampsia is unpredictable and the aetiology of pre-
eclampsia still remain unknown (Higgins & Brennecke，1998). One of the key aims 
of modem antenatal care is to detect pre-eclampsia as early as possible thereby 
allowing appropriate management. Unfortunately, no simple tests are currently 
available to do this (Shankar et al., 2004) and the detection of pre-eclampsia depends 
upon frequent antenatal visits in late pregnancy for blood pressure measurement and 
urinalysis. These approaches are both costly and neither particularly sensitive nor 
specific (Murray et al., 2002). Clearly, a sensitive, specific, cheap and non-invasive 
predictive marker of the pre-eclampsia would be an most important development. 
The presence of a placenta is necessary to cause pre-eclampsia. The fetus or the 
uterus is not the causative organ since pre-eclampsia can occur with hydatidiform 
mole and abdominal pregnancy (Page, 1938). The central role of the placenta in the 
pathogenesis of pre-eclampsia is undisputed. Classically, pre-eclampsia was 
described as a two-stage disorder (Redman, 1991). In the first stage, inadequate 
uteroplacental circulation leads to placental ischemia and the ischemic placenta 
releases circulating factor(s) into the maternal circulation and results in endothelial 
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dysfunction. In the second stage, endothelial dysfunction results in excessive 
inflammatory responses and lastly development of the maternal syndrome. 
2.1 Inadequate Uteroplacental Circulation 
In pre-eclampsia, it is generally considered that inadequate uteroplacental 
circulation leads to placental ischemia, and in the most severe case, infarction (Soma 
et al•，1982). Spiral artery abnormalities are known to predispose to the problem: the 
arteries may be either too small because of poor placentation, or obstructed because 
of acute atherosis. 
In normal pregnancy, placentation is the result of the interaction of extravillous 
trophoblast, endometrium and myometrium. The maternal spiral arteries are 
transformed into large structureless conduits by extravillous trophoblast invasion. 
The diameter of the spiral arteries increases dramatically while smooth muscle, 
neural tissue and inner elastic lamina of the vessel wall are lost (De Wolf et al., 
1982). The invading extravillous trophoblast cells that express endothelial surface 
antigens replace the endometrial endothelium (Zhou et al., 2002b). This spiral artery 
remodeling allows an uninterrupted huge supply of maternal blood to the placenta to 
meet the requirements of the fetus (Dekker & Sibai，1998). 
In pre-eclampsia, extravillous trophoblast invasion is impaired. Spiral arteries 
remain muscular and compared with normal pregnancy maternal blood flow to the 
placenta is relatively smaller, (van Beck & Peeters, 1998; Dekker & Sibai, 1998). 
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It is proposed that defective remodeling of the spiral arteries results in the 
retention of vasoreactivity of spiral arteries and that this leads to intermittent 
perfusion of the intervillous space, and hence ischemia-reperfusion within the 
placenta (Hung et al.，2002). 
However, while poor placentation is a predisposing factor for pre-eclampsia, it 
is not the sole cause of pre-eclampsia (Redman et al., 1999). It is relevant to note 
that fetal growth impairment is not a universal feature of pre-eclampsia, but only of 
the early onset of pre-eclampsia. In addition, restricted placentation can occur 
without pre-eclampsia in some pregnancies where the fetuses are small for 
gestational age (Brosens et al., 1977; Gerretsen et al., 1981). These women may not 
be susceptible to pre-eclampsia and therefore show only the fetal part of the 
syndrome of poor placentation. 
Acute atherosis is another cause of inadequate uteroplacental circulation. It is 
the obstruction of the spiral arteries. Most descriptions emphasize a component of 
necrosis, particularly affecting the media of the artery (Robertson et al., 1976). 
Deposition of fibrin thickens the intima. It is infiltrated by macrophages that 
accumulate fat and become foam cells. The lesions in their early stages are 
characterized by endothelial damage (De Wolf et al., 1982). The endothelial 
involvement may be a particular example of the generalized endothelial dysfunction 
characteristic of pre-eclampsia. 
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2.2 Placenta Ischemia 
It is expected that placental perfusion will be reduced in the context of the 
spiral artery pathology and lead to placental ischemia. Indirect measures of placental 
or uterine perfusion such as intravenous radioisotope techniques demonstrate 
reduced blood flow in pre-eclampsia (Kaar et al.，1980). Evidence of placental 
ischemia is provided by placental infarction. The most obvious macroscopic features 
of many pre-eclamptic placentae are infarcts (Wentworth, 1967)，though there may 
be infarcts without pre-eclampsia and conversely pre-eclampsia without infarcts 
(Little, 1960). Animal model demonstrated that reduced placental perfusion induced 
surgically can generate placental ischemia and development of hypertension 
(Cavanagh et al., 1985). In short, there is good evidence to confirm that placental 
ischemia underlies many cases of pre-eclampsia. 
2.3 Oxidative Stress 
Oxidative stress is a pathological state in which pro-oxidants, e.g. superoxide 
and peroxynitrite, dominates over antioxidants, e.g. vitamin E and cemloplasmin. 
The overall increase in the formation of reactive oxygen species (ROS) can damage 
cell membranes, proteins and DNA. A common pathologic source of ROS is the 
response to ischemia-reperfusion (Lum & Roebuck, 2001). It is postulated that in 
response to ischemia-reperfusion within the placenta in pre-eclampsia, ROS 
produced can alter endothelial cell function. 
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Mitochondria in the placenta from women with pre-eclampsia are more 
abundant than normal and are of abnormal appearance (Jones & Fox, 1980). It is 
proposed the abnormal mitochondria could lead to excessive electron leakage into 
the cytosol and local formation of superoxide radicals. The mitochondria also show 
evidence of oxidative damage as indicated by an increase in lipid peroxidation 
(Wang & Walsh，1998). 
The predominant source of ROS is likely to occur by generation through the 
xanthine oxidase/dehydrogenase pathway. With hypoxia and in response to several 
cytokines, xanthine oxidase/dehydrogenase synthesis is increased and the conversion 
of the enzyme to the xanthine oxidase form is enhanced (Terada et al.，1990). 
Ischemia and subsequent reperfusion are proposed to result in increased xanthine 
oxidase in the pre-eclamptic placental bed (Many et al., 2000). 
ROS may also originate from increased nitric oxide syntheses (NOS) activity in 
the placenta of pre-eclamptic subjects, which will increase synthesis of reactive 
nitrogen species; nitric oxide (NO) reacts with superoxide to generate peroxynitrite. 
Peroxynitrite residues, which are formed from peroxynitrite attacking plasma 
membrane proteins, have been observed in the villous vascular endothelium of 
placentae (Myatt et al., 1996) and in invasive trophoblasts of affected women (Many 
et al., 2000). These finding support ROS originate in the placenta of pre-eclampsia. 
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ROS in general are quite labile; nonetheless, there are several possibilities by 
which they may affect endothelium adversely. The simplest way would be oxidative 
injury by stable products of lipid peroxidation such as malondialdehyde, known to 
be increased in the plasma of pre-eclamptic women (Hubel et al.，1996). 
Alternatively, neutrophils and monocytes passing through the intervillous space 
could be activated by ROS and interact with endothelial cells to generate oxidative 
injury. This is supported by the observation that these cells are activated in pre-
eclamptic women (Clark et al., 1998). It has been shown that there is increased 
deportation of syncytial fragments in pre-eclamptic placenta (Knight et al., 1998) 
that the syncytiotrophoblast debris may itself be modified by oxidative stress. 
Circulating syncytiotrophoblast debris by its content of peroxidised lipids could be 
also potentially provided as a source of ROS (Cester et a l , 1994). 
2.4 Systemic inflammatory response 
Many lines of evidence support the view that the maternal syndrome of pre-
eclampsia is caused by a maternal systemic inflammatory response. The 
polymorphic nature of the inflammatory network may explain the diversity of the 
maternal syndrome. A key finding is that a maternal systemic inflammatory response 
is also a feature of normal third trimester pregnancy, but less severe than in pre-
eclampsia. 
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Pre-eclampsia is associated with a more extreme systemic inflammatory 
response than that occurs in normal pregnancy. The markers of inflammation that 
are already changed in normal pregnancy are more severely altered in pre-eclampsia. 
The markers of inflammation include leukocytosis (Terrone et al., 2000; Sacks et al.， 
1998)， complement activation (Haeger et al, 1989)， platelets activation 
(Konijnenberg et al., 1997)，clotting system activation (Terrone et al., 2000; Sacks et 
al., 1998; Haeger et al, 1989; Perry & Martin，1992; Konijnenberg et al., 1997; 
Taylor et al , 1991; Gratacos et al., 1998)，endothelial activation (Taylor et al., 1991) 
and oxidative stress (Gratacos et al , 1998). 
A systemic inflammatory response is a generalized activation of the innate and 
adaptive immune systems. The innate immune system is fast and relatively crude 
compared to adaptive immune system. An early systemic inflammatory response 
involves inflammatory leukocytes, such as monocytes and granulocytes, and a 
network of interacting components that include endothelium, coagulation system and 
complement systems. 
Endothelium is an active part of the innate immune system and that endothelial 
cells are fully functional immune cells (Henneke & Golenbock, 2002). They have 
many of the receptors that activate innate immune receptors, such as toll-like 
receptors, they can present antigen after appropriate stimulation, producing a range 
of pro-inflammatory cytokines such as tumor necrosis factor- a (TNF- a ) and 
stimulate, as well as be stimulated by inflammatory leukocytes . 
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Endothelial dysfunction in pre-eclampsia is well documented. Circulating 
markers of endothelial dysfunction include von Willebrand factor, thrombomodulin, 
cellular fibronectin, and tissue plasminogen activator. These are all increased in pre-
eclampsia (Calvin et al., 1988; Friedman et al., 1994). Increased plasma endothelin-1 
in women with pre-eclampsia also suggests the activation of deteriorated endothelial 
cells (Schiff et al., 1992). Plasma levels of various cell adhesion molecules such as 
vascular endothelial cell adhesion molecule-1 (VCAM-1) and growth factors such as 
vascular endothelial growth factor (VEGF) are also increased in pre-eclampsia 
(Lyall et al., 1995). VCAM-1，a cell surface glycoprotein expressed by cytokine-
activated endothelium, mediates the adhesion of monocytes and lymphocytes. It has 
been suggesting that inflammation and endothelial activation can result in activation 
of the coagulation cascade and production of fibrinogen (Ramsay et al., 2004). On 
the other hand, VEGF plays specific role in vasculogenesis and angiogenesis. VEGF 
increases microvascular endothelial cell prostacyclin production in a dose-dependent 
manner, analogous to the acute effects of plasma from patients with pre-eclampsia 
(Hayman et al., 1999). Similarly, in myographic studies, when myometrial resistance 
arteries are incubated with VEGF, there are dose-dependent alterations in 
endothelium-dependent behavior, mirroring those found after incubation with 
plasma from patients with pre-eclampsia (Brockelsby et al., 1999). It is well 
documented that the endothelium plays a role in haemostasis and thrombosis, 
producing a range of substances that promote or inhibit coagulation (Lyall et al., 
1995). These data support the notion of endothelial dysfunction in pre-eclampsia. 
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2.5 The Continuum Theory of Clinical Syndromes 
It has been proposed that pre-eclampsia is simply the extreme of the continuum 
of the systemic inflammatory response common to all pregnancies, with multiple 
contributing factors (Redman & Sargent, 2003). Any factor that would increase the 
maternal systemic inflammatory response to pregnancy would predispose to pre-
eclampsia. There are three possible factors: a large placenta; an abnormal stimulus 
from a small placenta; or an excessive maternal sensitivity to such stimuli. 
First, it is a clinical fact that pre-eclampsia is predominantly a disorder of the 
third trimester, when the placenta reaches its greatest size. The placenta grows larger 
with multiple pregnancies and gestational diabetes. These increase the likelihood of 
pre-eclampsia. Pre-eclampsia is also more likely with bigger, rather than smaller, 
hydatidiform moles (Llewellyn-Jones, 1967). 
Second, the most severe form of pre-eclampsia develops with intrauterine 
growth restriction is often associated with abnormally small placenta. Here, it is 
presumed that there is an alternation in the quality of the inflammatory stimulus 
generated by the placenta under oxidative stress. 
Third, there is the increase in sensitivities to the inflammatory stimulus in 
pregnancy. Dysfunctional endothelium is the convergence point of both maternal 
responses and placental stimuli which may show excessive sensitivity and triggers 
the maternal syndrome in pre-eclampsia. 
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2.6 Origin of Stimuli to Inflammatory Response 
Once the placenta is delivered, pre-eclamptic woman reliefed from the 
symptoms. The stimulus for the inflammatory responses should thought to originate 
in the placenta; the release during pregnancies can be atypically large when the 
placenta is oxidatively stressed. There are three candidate factors, cytokines, 
oxidative products or syncytiotrophoblast debris. 
It has been hypothesized that cytokines such as TNF- a and (interleukin-1) IL-1 
are overproduced by the placenta in response to local ischemia/hypoxia contributing 
to increased plasma levels, and subsequent endothelial activation and dysfunction in 
pre-eclampsia (Conrad & Benyo，1997). Syncytiotrophoblasts and fetoplacental 
macrophages normally produce TNF- a and IL-1, which are capable of causing 
endothelial cell activation and dysfunction (Guilbert et al., 1993). It has been 
reported that hypoxia increases TNF- a and IL-1 production by term villous 
explants from the human placenta (Benyo et al., 1997). However, there is no 
convincing evidence yet that the pre-eclamptic placenta disseminates inflammatory 
cytokines into the maternal circulation. 
As discussed above, in response to ischemia-reperfusion, the placenta produces 
excessive ROS in pre-eclampsia that activates leukocytes and alters endothelial cell 
function. 
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Syncytiotrophoblast debris is another candidate of stimuli. It is detected in the 
maternal circulation of normal pregnant women but in significantly increased 
amounts in pre-eclamptic women (Knight et al., 1998). Syncytiotrophoblast debris 
causes direct damage to endothelium by inhibiting endothelium growth in vitro 
(Smarason et al., 1993). It is also pro-inflammatory and activates neutrophils (von 
Dadelszen et al., 1999) and peripheral blood leukocytes (von Dadelszen et al., 1999). 
It was proposed that syncytiotrophoblast debris are part of a large burden of cellular, 
sub-cellular and molecular debris shed from the syncytial surface whose clearance 
comprises the systemic inflammatory response in normal and pre-eclamptic 
pregnancies (Redman & Sargent，2000). Such debris is probably the product of 
syncytial apoptosis and necrosis. Both apoptosis and necrosis are known to be 
increased in pre-eclampsia (Ishihara et al., 2002; Soma et al., 1982). 
Apoptosis is an active cell death process. Cells are induced to commit suicide 
by the activation of an intrinsic programme. Firstly, the apoptotic cells shrink, next 
the mitochondrial membrane potential breaks down and mitochondria release 
cytochrome c and lastly, chromatin condenses. The apoptotic cell breaks into small, 
membrane-wrapped fragments that are engulfed by phagocytes. The release of 
apoptotic material does not lead to an inflammatory response of the mother. (Searle 
et al., 1982). 
Necrosis is an accidental cell death process. Cells are damaged by injury and 
die. The whole cell together with its organelles, such as the nucleus and 
14 
mitochondria, swell because the plasma membrane is no longer able to control the 
passage of ions and water. Thus the cell contents leak out, resulting inflammation of 
surrounding tissues (Searle et al., 1982). 
The human placenta consists of an extensively branched fetal villous tree that is 
bathed by the maternal blood circulating in the intervillous space. The contact 
surface between the fetal placental tissues and the maternal blood is the 
syncytiotrophoblast, a multinucleated syncytium that extends with lateral cell 
boundaries over the entire villous tree. Apoptosis is a normal constituent of 
trophoblastic turnover (Huppertz et al., 2002). During pre-eclampsia there seems to 
be an altered balance between proliferation and apoptosis of villous trophoblast 
leading to a dysregulation of the apoptotic release (Huppertz & Kingdom, 2004). 
Since apoptosis is still ongoing in the syncytiotrophoblast, necrotic intrasyncytial 
and partly apoptotic materials result in apopnecrotic shedding (Huppertz & 
Kingdom, 2004). In this situation, cell-free components such as G-actin and DNA 
fragments freely floating in maternal blood may trigger damage to the maternal 
endothelium, thereby resulting pre-eclampsia. 
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Chapter 3 Proteomic Analysis 
Proteins are key structural and functional molecules in living cells; they are 
manufactured according to the blueprint of the genome. The proteome, the array of 
proteins expressed in a biological compartment (cell, tissue, organ) is dynamic, it 
changes with time and changes according to the physiological state. Because 
proteins are key structural and functional molecules, understanding of the proteome 
allows a better understanding of biological systems. 
Proteomic analysis is a large-scale, comprehensive analysis of proteins. It 
encompasses identification and quantification of proteins in cells, tissues and 
biological fluids, analysis of changes in protein expression in normal versus diseased 
cells; characterization of post-transnational modifications, and studies of protein-
protein interactions (Anderson & Anderson，1998). Proteomic research allows 
clarification of molecular mechanisms that govern cellular processes, 
characterization of complex protein networks and their perturbation, discovery of 
biomarker proteins for prognosis and diagnosis of diseases, and identification of 
targets for the drug design (Wu et al, 2002). 
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3.1 Methodology in Proteomic Research 
Proteomic research was made possible in the mid-1990s only because of 
concurrent advances in three areas: two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE); mass spectrometry (MS) methods, and bioinformatics 
tools. Other advances in technology such as antibody microarray and surface-
enhanced laser desorption/ionization time-of-flight mass spectrometer (SELDI-TOF-
MS) have also expanded proteomics research. Here, only 2D-PAGE, MS and 
bioinformatics tool will be discussed in detail. 
3.1.1 2D-PAGE 
2D-PAGE has evolved into a robust method to rapidly separate many proteins 
contained in a proteome extracted from a biological sample. It separates proteins 
according to two independent properties (O'Farrell, 1975) in two discrete steps: the 
first dimension separation, isoelectric focusing (lEF), separates proteins according to 
their isoelectric points (pi); the second dimension separation, SDS polyacrylamide 
gel electrophoresis (SDS-PAGE), separates proteins according to their sizes, which 
are directly proportional to the molecular weights. Each discrete spot on the 
resulting two-dimensional images corresponds to a single protein species in the 
sample. Hundreds to thousands of different proteins can be separated 
simultaneously. 2D-PAGE is also unique in its ability to detect post-and co-
translational modifications, which cannot be easily predicted from the gene 
sequence. Using this technology, the protein information of pi value, apparent 
molecular weight and the quantity of each protein can be obtained. 
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3.1.2 Mass Spectrometry 
MS methods have been developed for ready and accurate analysis of 2D-PAGE 
separated proteins with high sensitivity and specificity. Proteins resolved by 2D-
PAGE can be identified based on unique attributes that are measured by MS. These 
attributes are determined from analysis of peptides generated by proteolytic 
digestion of the protein of interest. Two specific protein attributes can be obtained 
by MS analysis of proteolytic digests. The first protein attribute is the peptide mass 
fingerprint and the second is the peptide product-ion data (Beranova-Giorgianni, 
2003). 
3.1.2.1 Peptide Mass fingerprinting 
Peptide mass fingerprinting involves determination of the masses of all peptides 
in the digest. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS) is commonly used for determination of the masses 
of peptides (Yates, 1998b). With MALDI-TOF-MS, the sample to be analyzed is 
mixed with a chemical matrix and then spotted onto a plate. The matrix chemicals 
absorb photons from the beam and become electronically excited. This excess 
energy is then transferred to the peptides in the sample, the majority of which forms 
singly charged peptide ions, and are desorbed from the sample plate into the gas 
phase. The mass/charge ratios of the peptide ions formed in the MALDI source are 
then measured with TOF mass analyzer. Finally, the profile of mass values of the 
peptide ions is subjected to database search and the protein is identified (Wu et al., 
2002). 
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3.1.2.2 Product-ion Data 
Product-ion data is used for deducing the partial amino sequence of the protein 
of interest. It complements the peptide mass fingerprinting for identification of 
protein. Liquid chromatography-electrospray ionization-quadmpole-ion trap tandem 
mass spectrometry (LC-ESI-MS/MS) is usually employed (Beranova-Giorgianni, 
2003). Product-ion data is acquired through selection, isolation and fragmentation of 
a peptide (precursor ion) within the LC-ESI-MS/MS. Peptides in a tryptic digest are 
firstly separated by liquid chromatography. A peptide of interest is then selected, 
isolated and fragmented. The fragmentation occurs mainly in the peptide bond of the 
amino acid chain backbone, generating a ladder of sequence ions (Hunt et al., 1986). 
Finally, the resulting peptide fragment mass spectrum subject to database search and 
the protein is identified. 
3.1.2.3 Matrix-assisted Laser Desorption/Ionization Tandem Time-of-Flight 
Mass Spectrometry (MALDI-TOF/TOF MS) 
MALDI-TOF/TOF MS is one of the latest generations of MS instrument. It has 
the combined function of MALDI-TOF-MS which can generate peptide mass 
fingerprinting (peptide mass spectrum) and tandem mass spectrometer (MS/MS) 
which can generate product-ion data (peptide fragment mass spectrum) through its 
high energy collision-induced dissociation capabilities (Medzihradszky et al., 2000). 
Furthermore, both peptide mass fingerprinting and product-ion data can be recorded 
on a single instrument using the same portion of the proteolytic digest of a sample. 
In my study, the 4700 Proteomics Analyzer, a MALDI-TOF/TOF MS was employed. 
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3.1.3 Bioinformatics Tools 
Large-scale genome research has produced a constantly increasing number of 
sequences that are catalogued in several databases, which can be accessed over the 
Internet. Search engines and other bioinformatics tools have been developed to 
query these databases. Peptide mass fingerprinting and product-ion data are 
subjected to sequence database searches to identify the protein of interest. The 
identification is made by comparing the experimental data with theoretical data 
calculated for each database entry (Yates, 1998a). The principle is to retrieve 
proteins that would produce the same set of data if digested and analyzed in the 
same manner as the protein under study. Usually, a list of candidate proteins that 
mostly match the input data is generated by the search, and the candidate proteins 
are ranked using various scoring algorithms (Beranova-Giorgianni, 2003). 
3.2 Applications of Proteomic Analysis 
combinded use of 2D-PAGE, MS and bioinformatics form a robust approach 
for proteomic analysis. This 2D-PAGE based proteomic approach has been widely 
applied in medical research to study cancer (Omstein et al., 2000; Jones et al., 2002; 
Zhou et al., 2002a; Alaiya et al., 1999; Franzen et al., 1997)，viral or bacterial 
infections (Bini et al., 1996)，cardiomyopathic heart disease (Scheler et al., 1999) 
and neurodegenerative diseases like Alzheimers (Davidsson et al., 2002) or 
Huntington's chorea (Zabel et al., 2002) for discovery of biomarkers and drug 
targets. 
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Chapter 4 Materials and Methods 
4.1 Overview 
The objectives of this study were achieved in 3 stages (Figure 4.1). 
Stage 1: 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) analysis of the 
plasma of pre-eclamptic and non-pre-eclamptic women 
Stage 2: 
Mass spectrometry analysis of the pre-eclampsia-associated plasma protein(s). 
Stage 3: 
Immunoassay validation of the identified plasma protein(s). 
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Pre-eclampsia was considered established when a sustained rise in diastolic 
blood pressure to at least 110 mmHg on one occasion or at least 90 mmHg on two or 
more occasions at least four hours apart, with the presence of the significant 
proteinuria in subjects with no history of pre-existing or chronic hypertension was 
evident. Significant proteinuria was defined as proteinuria higher than 0.3 g/day or at 
least ++ on dipstick testing in two clean-catch midstream urine specimens collected 
at least four hours apart (International Society for the Study of Hypertension in 
Pregnancy, Davey & MacGillivray, 1988). 
4.2.2 Recruitment 
Pregnant women attending the Department of Obstetrics and Gynaecology at 
the Prince of Wales Hospital, teaching hospital of the Chinese University of Hong 
Kong from September 2003 to December 2004 for antenatal check-up, were 
recruited with written and informed consent. Ethics approval was obtained from the 
Research Ethics Committee of the university. Only singleton pregnancies were 
included. The gestational age of the studied subjects was confirmed by early 
ultrasound examination. 
Ten ml of maternal blood were collected from the antecubital vein of the 
subjects complicated by pre-eclampsia. Ten ml of maternal blood were also 
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collected from control pregnant women who had no medical and antenatal 
complications. Both the pre-eclamptic and control subjects were matched for 
gestational age at the time of blood sampling. The patient inclusion criteria are based 
on the research definition used by the Genetics of Pre-eclampsia Collaborative Study. 
4.3 Stage I: Comparative Proteomic Analysis 
4.3.1 Sample Processing 
Ten ml whole blood were collected and placed immediately into EDTA blood 
collecting tubes. Samples were centrifuged at 3000 rpm for 10 min at 4 °C. Then the 
supernatant (plasma) was aliquoted into plain polypropylene tubes. The plasma was 
stored at —80 °C until analysis. Plasma albumin was depleted (as stated in the 4.3.3) 
and plasma protein concentration was determined by modified Bradford's method. 
4.3.2 Modified Bradford's Method 
For (2D-PAGE) analysis, the same amount of proteins has to be loaded onto the 
gel for each plasma sample. Before sample loading, the plasma total protein of each 
sample was quantified. Modified Bradford's Method was adopted to measure the 
protein concentration in plasma. The method is based on the proportional binding of 
the Coomassie dye to proteins. The Coomassie blue G250 appears to bind to arginyl 
and lysyl residues of proteins (not to the free amino acids) and the colorimetric 
Coomassie blue absorbs at 595 nm. Within the linear detection range of the assay, 
the more proteins are present, the more Coomassie blue binds. 
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The Coomassie Brilliant Blue G-250 solution was prepared as indicated in the 
appendix. One hundred and ninety /xl of Coomassie Brilliant Blue G-250 (CBB, 
Sigma-Aldrich, USA) solution was added to each well of a microplate (Sero Wei, 
Bibby Sterilin). The background absorbance of each well was measured at a 
wavelength of 595 nm in a microplate reader (SPECTRA Rainbow, Tecan, Austria, 
Austria). Ten /xl of standard [Bovine serum albumin (BSA), 0，20, 50 and 100 ng / jA 
]o r diluted sample (1000-fold dilution) was added to individual wells in duplicate. 
The microplate was shaken for 6 min. The final absorbance of each well was 
measured at 595 nm. The change of absorbance was calculated: 
A absorbance = final absorbance - background absorbance. 
A absorbance of the standards was plotted against protein concentrations to 
obtain the standard curve. The protein concentration in plasma sample was 
calculated from the standard curve with a quadratic equation. 
4.3.3 Albumin Depletion 
Since albumin is a protein which comprises about 50% of the blood plasma 
protein. Removal of albumin allows visualization of proteins co-migrating with 
albumin on 2-D PAGE and improvement in the detection of low abundance proteins. 
Blue SepharoseTM CL-6B bead is CibacronTM Blue F3G-A dye covalently 
attached to Sepharose CL-6B bead. Albumin will be depleted by the electrostatic 
and/or hydrophobic interactions with the aromatic anionic ligand of Cibacron™ 
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Blue F3G-A dye. Nine hundred Blue Sepharose CL-6B (0.125 g/ |li1, Amersham 
Biosciences, Sweden) in phosphate buffer saline (IX PBS, Amresco, USA) was 
transferred to a spin column (Handee Mini Spin, Pierce, USA) with a three ml 
syringe. The spin column packed with Blue Sepharose CL-6B was placed in a 
collection tube (1.5 ml). The syringe was rinsed with double distilled water (dd H2O) 
and then filled with two ml Tris buffer (20 mM Tris, pH8.3). The spin column was 
washed with Tris buffer. 2500 jLig plasma protein sample was diluted with Tris buffer 
to 3 folds of it original volume and was then added into the spin column. The sample 
was incubated at room temperature for 10 min. The spin column was centrifuged at 
10,000 g for 30 s and the eluate was collected. The volume of elute was recorded, 
and plasma protein concentration of the eluate was measured again using modified 
Bradford's method. The eluate was dilute 50 folds for quantification. After 
quantification, 100 /zg albumin depleted plasma protein of each sample was 
subjected to 2D-PAGE analysis. 
4.3.4. Comparative Proteomic Analysis 
Plasma proteins were separated by 2D-PAGE in 2 discrete steps. In the first-
dimension separation, proteins were separated according to their isoelectric points 
(pi) by isoelectric focusing (lEF). In the second- dimension separation, proteins 
were separated according to their molecular weights by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 4.2). Each pair of 
gestation age matched normal and pre-eclamptic samples were analyzed in duplicate 
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Figure 4.2. Separation of plasma proteins by two-dimensional polyacrylamide 
gel electrophoresis (2D-PAGE). Proteins were separated by isoelectric focusing 
(lEF) and then sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). 
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4.3.4.1 First Dimension: Isoelectric Focusing (lEF) 
Proteins are amphoteric molecule. When proteins are subjected to an electrical 
field in a medium with a pH gradient, they will migrate to the point at which they are 
at the net charge of zero. 
After albumin depletion, the plasma proteins were buffer in Tris, pH 8.3. Since 
this buffer is not compatible to lEF，buffer should be exchanged before proceeding 
to lEF. After quantification, 100 fig plasma protein was concentrated to 20 fil by a 
concentrator (Microcon YM-10, Millipore, USA) at 14,000 g, 15°C for 40 min. A 
hundred fil of rehydration buffer (ReadyPrep 2-D Starter Kit Rehydration/ Sample 
Buffer, Bio-Rad, USA) was added to the sample. The sample was centrifuged at 
14,000 g, 15�C for 40 min. These 2 steps were repeated until the dilution change was 
larger than 1000 fold. The final upper reservoir of concentrator was top up to 300/^ 1 
with rehydration buffer and was transferred to a new collection tube. 
A 17cm pH 3-10 non-linear isoelectric focusing (lEF) strip (Readystrip pH 3-
lONL, 17cm, Bio-Rad, USA) was rehydrated with a sample of 100 fig plasma 
protein in 300 |li1 rehydration buffer for 15 hrs. Then the sample pre-loaded lEF strip 
was subjected to first dimension lEF with different voltage gradient as the 
programme in Table 4.1. 
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Table 4.1. Programme for lEF. 
Total time: 7 hours 
Maximum current: 50 fiA per gel 
Temperature: 2Q°C  
— S t e p Mode Voltage (V) Time(hr) 
01/08 Linear 100 00:30 
02/08 Linear 200 01:00 
03/08 Linear 500 01:00 
04/08 Linear 1000 01:00 “ 
05/08 Linear 8000 00:30 
06/08 — Rapid 8000 03:00 
07/08 Rapid 500 — 03:00 
08/08 Rapid 500 15:00 
4.3.4.2 Reduction and Alkylation 
Before being subjected to second dimension SDS-PAGE, the lEF strip was 
subjected to reduction with dithiothreitol (DTT) and alkylation with iodoacetamide 
(lAA). DTT reduces disulfide bonds at cysteine residues; lAA alkylates the 
sulfhydryl groups to keep the site permanently reduced. These treatments convert all 
proteins to their monomer and help preventing from streaking, pi alternation and 
also enable the transfer of higher amounts of protein from the lEF strip into the SDS 
gel later. 
The strip was rinsed with ultrapure water. The gel was equilibrated in 5 ml of 
equilibration buffer I [6M Urea (Sigma-Aldrich, USA), 0.375M Tris-HCl (Sigma-
Aldrich, USA) pH 8.0, 2% SDS (Sigma-Aldrich, USA) and 20% glycerol 
(Amresco，USA)] with 1% dithiothreitol (DTT, Sigma-Aldrich, USA) for 20 min. 
Next, the gel was equilibrated in 5 ml of equilibration buffer II (6M Urea, 0.375M 
Tris-HCL pH 8.0 and 20% glycerol) with 4% iodoacetamide (lAA, Sigma-Aldrich, 
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USA) for 20 min. Finally, the gel was equilibrated in 5 ml of equilibration buffer I 
again for 15 min. 
4.3.4.3 Second Dimension: SDS-PAGE 
SDS denatures proteins and forms negatively charged protein-SDS complexes. 
The amount of SDS bound to a protein is directly proportional to the mass of the 
protein. Therefore, proteins have similar mass to charge ratio and electrophoresis of 
proteins through a sieving gel separates proteins on the basis of molecular weight. 
The lEF strip from the first dimension was applied on the top of precast gel 
(PROTEAN II Ready Gel Tris-HCl Gel, 8-16 %，Bio-Rad, USA). The position of 
the lEF strip was secured by overlaying with 1% agarose. The precast gel was 
assembled into the running cassette of PROTEAN II XL Vertical Electrophoresis 
Cell (Bio-Rad, USA). Tris/ Glycine /SDS buffer (IX，Bio-Rad, USA) was used as 
the running buffer for the second dimension. 
Protein was separated in SDS-PAGE with a three-step electrophoresis 
programme. Firstly, the protein loaded gel was subjected to constant current of 
16mA for 45 min for stacking. Next, it was subjected to constant voltage of 150V for 
15 hrs for protein separation. Lastly, it was subjected to constant current for 10mA 
for 3 hrs for damping. 
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4.3.4.4 Gel Imaging 
Firstly, gel fixation prevents the diffusion of proteins, thus keeping the 
protein spots sharp and resolved during the staining. The gel was washed with 
200 ml double distilled water. And then the gel was fixed with 200 ml fixing 
solution [10 % acetic acid glacial (AnalaR) in 40 % ethanol (MERCK, 
GERMANY)] for half an hour. 
Secondly, silver staining techniques were employed to visualize the 
plasma proteins separated in 2D-PAGE. This enables later image analysis. 
Silver staining is a sensitive non-radioactive method, which can detect protein 
below 1 ng in the 2D-gel. The gel was stained with silver staining kit (Silver 
Staining Kit, Protein, Amersham Biosciences, Sweden, Sweden) according to 
the protocol in the manufacturer's manual. Briefly, the 2D-gel was sensitized 
with 0.2%(v/v) sodium thiosulphate and 6.8%(w/v) sodium acetate solution. 
Next, it was stained with 0.25%(v/v) silver nitrate solution. Then the image was 
developed with sodium carbonate and the development was stopped with 
EDTA solution. 
Lastly, gel images were acquired by the GS-700 Imaging Densitometer 
(Bio-Rad，USA) with software Quantity One (Bio-Rad, USA). 
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4.3.5 2D-PAGE Data Analysis 
Protein spots on the gel image were automatically detected and matched. Then 
the protein spots were quantified with The Discovery Series PDQuest 2-D Analysis 
Software (Version 7.1.1, Bio-Rad, USA). 
4.3.5.1 Gaussian Spot 
In PDQuest, the scanned gel image is filtered and smoothed to clarify the spots 
by background subtraction and streaking removal. Then three-dimensional Gaussian 
spots (Figure 4.3) were created from those clarified spots. A Gaussian spot is a 
three-dimensional representation of an original scanned spot. Gaussian curves are 
fitted to the scanned spot in the X and Y dimensions, and then additional modeling is 
performed to create the final Gaussian spot. Because the image profile of an ideal 
spot conforms to a Gaussian curve, by using Gaussian modeling, one can accurately 
quantify the intensity of overlapping spots, spots in gel streaks and multiple spots in 
dense clusters. 
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Figure 4.3. 3D view of a typical Gaussian spot. 
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4.3.5.2 Matchset 
After detection of the spots in the set of gels, a matchset of normal pregnant and 
pre-eclamptic plasma was created. In a matchset, the protein spots from the different 
gels were matched to each other with manual adjustment and were included in a 
synthetic image called matchset standard. The standard included all the information 
about the spots in the matchset. 
The dynamic range of plasma proteins is very large. In order to visualize the 
low abundant proteins, the high abundant proteins were often over-stained 
intentionally for comparison So the over-stained spots have to be excluded for 
reliable normalization of protein spot quantity. 
Protein spots were used for further analysis only if they were not over-stained 
and present in more than 50% of the total number of gels. In this experiment, the 
information from high abundant proteins (over-stained spots) was sacrificed and 
only the information from the low abundant proteins was focused. It has been 
proposed that low abundant proteins were potentially disease-related proteins. 
4.3.5.3 Normalization 
The quantities of matched spots were then exported to an Excel file and 
normalized. When comparing gels in a matchset, there are often some variations in 
spot size and intensity between gels not related to differential protein expression. 
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This variation can be caused by a number of factors, including handling errors 
resulting in some sample loss during preparation, pipetting errors during sample 
preparation, sample loss during gel loading and inconsistent staining time between 
gels. To accurately compare spot quantities, normalization is needed to compensate 
for these non-expression-related variations in spot intensity. 
Normalization was performed for each gel in a matchset using the following 
formula: 
Normalized spot quantity (%) =Raw spot quantity X Scaling factor / 
Normalization factor X 100 
Raw spot quantity was the unnormalized quantity of each spot. 
Scaling factor was a factor transforming the spot quantity so that it can be 
comparable to the concentrations of protein measured in immunoassays. 
Normalization factor was the sum of the spot quantities between the 
quartile to the quartile. 
4.3.5.4 Significance Analysis of Microarrays 
Normalized spot quantity data was analyzed by Significance Analysis of 
Microarrays (SAM, Stanford University; (Tusher et al, 2001). SAM identifies 
protein spot quantity with statistically significant changes in expression by 
assimilating a set of protein specific t tests. Each protein is assigned a score on the 
basis of its change in term of protein expression relative to the standard deviation of 
repeated measurements for that protein. Proteins with scores greater than a threshold 
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are deemed potentially significant. The percentage of such protein identified by 
chance is the false discovery rate (FDR). To estimate the FDR, nonsense proteins are 
identified by analyzing permutations of the measurements. The threshold can be 
adjusted to identify smaller or larger sets of protein, and FDRs are calculated for 
each set. 
4.4 Stage II: Protein Identification 
Differentially expressed protein spots defined by SAM analysis were excised 
from the 2D-gel and subjected to in-gel trypsin digestion. The peptide mass and 
intensity were then measured with 4700 Proteomics Analyzer (Applied Biosystems, 
USA). A peptide mass spectrum unique to the protein of interest was generated 
(Figure 4.4). The peptide mass list was used for database search. Each experimental 
peptide mass list was compared with the theoretical mass list of each entry in the 
database, protein was identified. To confirm identification, the most intense peptides 
from the peptide mass lists were subjected to further fragmentation with 4700 
Proteomics Analyzer. A peptide fragment mass spectrum unique to the peptide was 
generated. The peptide fragments mass list was then subject to a database search and 
protein identity was confirmed. 
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Figure 4.4. Protein identification by mass spectrometry method. 
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4.4.1 Tryptic Peptide Fingerprinting 
Tryptic peptide fingerprinting involves 5 steps: removal of silver ions, 
reduction and alkyation, in-gel digestion, purification of peptides and peptide mass 
fingerprinting. 
4.4.1.1 Removal of Silver Ions 
Silver ion in protein spots induces background interference and suppression of 
signals in mass spectrometry analysis. Sliver ions must be removed from the protein 
spots before being subjected to mass spectrometry. Chemical reducing agents, 
potassium ferricyanide (III) and sodium thiosulphate could be used for the 
destaining procedure or commercial available reducing agents could be used. Our 
current protocol was adopted from instruction for commercial reducing agents, 
Destainer A and B (SilverQuest, Invitrogen, USA). 
Silver stained gel spots or blank gel spot were manually cut and put into a 
siliconized plastic tube. They were washed with 500 /xl ultrapure water and shaken 
for 10 min. The gel spots were destained with 200 [i\ freshly prepared destaining 
solutions Destainer A and B and shaken for 10 min. The procedures were repeated 
until the brown color of gel spot disappeared. To prevent diffusion of protein, the gel 
spots were washed twice with 500 50 % methanol/ 10 % acetic acid for 10 min. 
Then the gel spots were equilibrated twice with 500 fii ammonium bicarbonate 
solution (NH4HCO3, 100 mM, Sigma-Aldrich, USA) and shaken for 10 min. The 
gels was dehydrated twice with 500 fi\ NH4HCO3 750% acetonitrile (ACN，25mM) 
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for 10 min. The gel was dried in vacuum centrifugal concentrator (Centri Vap, 
Labconco, USA) for 15 min. 
4.4.1.2 Reduction and Alkylation 
Reduction and alkylation reduce and block free sulfhydryl groups to clarify 
spectra for peptide mass fingerprinting. Samples resulted from 2D-PAGE were 
reduced and alkylated between the lEF and SDS steps, thus these procedures are 
optional but recommended. 
The gel spots were reduced in 200 fil lOmM DTT in NH4HCO3 (25 mM) 
solution at 56°C for 30 min. Once the solution was removed, it was immediately 
alkylated with 200 50 mM lAA in NH4HC03 (25 mM) solution at room 
temperature in dark for 40 min. The gel was washed with 500 /il NH4HCO3 (100 
mM) solution and shaken for 10 min. The gel was dehydrated twice with 500/^ 1 of 
25 mM NH4HCO3 / 50 % ACN for 10 min and then dried in vacuum centrifugal 
concentrator for 15 min. 
4.4.1.3 In-gel Digestion 
The gel was rehydrated with 10 jul of trypsin solution (20 ng/jul in 25 mM 
NH4HCO3 / 10% ACN, pH 8.0，Promega, Germany) and incubated at 37�C 
overnight. The peptides were extracted twice with 20 /xl 50% ACN / 0.2% 
trifluoroacetic acid (TFA) solution with vigorous shaking for 5 min and were 
transferred into a new plastic tube. The remaining peptides were extracted with 10 fi\ 
of ACN solution (100%) at room temperature for 10 min and were pooled with the 
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previous collection. The peptide extract was dried in dry in a vacuum centrifugal 
concentrator for 15 min.. The peptides were re-dissolved with 5 fxl 50 % ACN / 0.2 
% TFA solution and vigorous shaken. 
4.4.1.4 Clean up of Peptides 
Trypsinized peptides were cleaned up with ZipTip CI8 (Millipore, USA). Five 
/xl sample from in-gel digestion was acidified with 50 /al 1% TFA solution before 
clean up. ZipTip CI8 was equilibrated with 70% ACN, 0.1 % TFA solution (pipette 
volume set to 10 /il) and then 50% ACN, 0.1% TFA solution. The ZipTip C18 was 
washed with 0.1 % TFA solution twice. Sample was pipetted up and down slowly in 
ZipTip CI8 for 10 times. The ZipTip C18 was washed with 0.1% TFA for 3 times. 
Sample peptides eluted with 5 /xl of 50 % ACN, 0.1 % TFA solution. 
4.4.1.5 Mass Spectrometric Analysis 
Three /xl cleaned up peptides were spot on a metallic plate. Point three fil matrix 
Alpha-cyano-4-hydroxy cinnamic acid [(CHCA, 3 mg/ fil) (Fluka, USA)] in 5 mM 
ammonium dihydrogenphosphate solution [(NH4H2PO4) (Fluka, USA)] was spotted 
over the samples. The samples were dried completely and then subjected to 4700 
Proteomics Analyzer (Applied Biosystems, USA) for MS and MS/MS analysis. 
4700 Proteomics analyzer has the combined function of Matrix-assisted Laser 
Desorption/Ionization Time-of-flight Mass Spectrometer (MALDI-TOF-MS) which 
can generate peptide mass spectra (peptide mass fingerprinting) and tandem mass 
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spectrometer (MS/MS) which can generated fragment mass spectra [collision 
induced dissociation (CID) mass spectra]. 
4.4.2 Database Search: Profound-Peptide Mapping 
A peptide mass spectrum that was unique to the protein of interest was 
generated. The peptide mass list was subjected to a database search. Database search 
was performed using an Internet available programme, Profound 
(http://prowLrockefeller.edu/profound bin/WebProFound.exe). The following 
parameters were used in the search: protein mass ranged from 10-100 kDa; trypsin 
digest: one missed cleavage allowed; peptide mass tolerance: 士 0.05 kDa; and 
species: Homo sapiens. NCBInr database was searched. Profound computed the 
normalized probability base on peptide mass list, experimental conditions and other 
background information. Candidate proteins were ranked from the highest 
probability to the lowest probability. The best match was ranked the first. Protein 
would be considered correctly identified with the highest probability equal to 1. 
4.4.3 Database Search: Mascot-MS/MS Ion Search 
To confirm identification, the most intense peptides from the peptide mass lists 
were subjected to further fragmentation by 4700 Proteomics Analyzer. A peptide 
fragment mass spectrum unique to each of the selected peptide was generated. The 
peptide fragment mass list was then subjected to a database search. Database search 
was performed using an Internet available programme, MS/MS Ion Search, Mascot 
(http://www.matrixscience.com/search form select.htmiy The following parameters 
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were used in the searches: protein mass ranged from 10-100 kDa; trypsin digest: one 
missed cleavage allowed; peptide mass tolerance: 士 0.05 kDa; fragment ion mass 
tolerance: 士 0.5 kDa; and species: Homo sapiens. MSDB database was searched. 
The protein identity was then confirmed. Moscot computed the probability based on 
the Mowse score. Candidate proteins were ranked from the highest probability to the 
lowest probability. The best match was ranked the first. For each peptide (precursor) 
ion, an individual Mowse score was assigned. P-value (<0.05) following the Mowse 
score was showed if protein was significantly identified based on that precursor ion. 
4.5 Stage III. Immunoassays 
To validate the plasma level of proteins found in comparative 2D-PAGE are 
different between normal pregnant women and pre-eclamptic women, sandwich 
Enzyme Linked Immuno-absorbent Assay (ELISA) was performed. In sandwich 
ELISA, antibody of specific protein was used as capturing antibody and bound to a 
solid phase. Antigen (protein of interest) was then added and allowed to complex 
with the bound antibody. Unbound products are then removed with a wash, and a 
second antibody was used as detection antibody and was allowed to bind to the 
antigen, thus completing the sandwich. Quantitative information was obtained by 
measuring the amount of second antibody bound complex, through the use of a third 
horseradish peroxidase conjugated antibody and colorimetric substrate. Plasma of 
normal pregnant women and pre-eclamptic women collected form another 
prospective cohort was used in validating the proteomic result. 
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4.6 Sample Size and Power Calculations 
In microarray or proteomic studies, to achieve a mean difference of 2 times 
larger than the pooled standard deviation in the signal intensity of the expression 
profiles with the predefined confidence and power of 95% (i.e. type I error = 0.05 
and type II error = 0.05), a minimum sample size of 8 from each arm (16 in total) is 
required to demonstrate the significant differential gene or protein expression 
(Hwang et al., 2002). 
4.7 Statistical Analysis 
Correlations between gestational age and concentrations of candidate protein(s) 
in normal pregnant women were analyzed by Spearman's correlation. Differences of 
numeric variables between normal pregnant women and pre-eclamptic women were 
analyzed by Mann-Whitney U test for independent samples and Wilcoxon Signed 
Ranks test for paired samples. Differences of dichotomous variables between normal 
pregnant women and pre-eclamptic women were analyzed by Pearson Chi-Square 
test. Their diagnostic values were determined by ROC curve. A p-value < 0.05 was 
considered as statistical significance. 
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Chapter 5 Results 
5.1 Patient's Demographic Characteristics and Obstetric 
Outcomes for 2D-PAGE Analysis 
The patient's demographic characteristics and obstetric outcomes for 2D-PAGE 
analysis were summarized in Table 5.1. There was no significant difference in age， 
maternal height, body weight before pregnancy, gravidity, final body weight, 
gestation at blood collection, haemoglobin, platelet count, white blood cell count 
(WBC), nulliparity and sex of infant between the normal pregnant women and pre-
eclamptic women. Maximum systolic blood pressure at delivery (Max sbp)， 
maximum diastolic blood pressure at delivery (max. dbp) and proteinuria were 
significantly lower in normal pregnant women. Gestation at delivery, placental 
weight, birth weight and normal spontaneously delivery were significantly higher in 
normal pregnant women. 
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Normal Pregnant Women Pre-eclamptic Women Wilcoxon Signed Ranks Test 
Number of cases 11 11 p-value (2-tailed)  
Mean Minimum Maximum Mean Minimum Maximum p-value  
Age (years old) ~ 29.18 ~ l 4 ! 0 0 ~ 33.00 “ 31.55 18.00 ~ 4 0 0 0 ~ 0.199 N.S. 
Maternal height (cm) 157.59 ~ 4 6 . 2 0 174 .00~ 159.32 150.00 ~ 6 6 . 0 0 0.441 N.S. 
Body weight before pregnancy (kq) ~ 50.52 " ~ 4 0 l 0 ~ 68.00 “ 58.78 41.00 0.161 N.S. 
Gravidity 1.91 ~ T 0 0 ~ 3.00 “ 2.30 ~ T 0 0 ~ 4.00 ~ 0.129 — N.S. 
Max sbp (mmHg) 118.45 103.00 139.00 173.09 135.00 210.00 0.003 . S. 
Max dbp (mmHg) 70.82 64.00 81.00 103.18 80.00 1 1 5 . 0 ^ 0.003 S. 
Proteinuria (no. of positive sign) ~ 0 . 0 0 0.00 0 . 0 0 ~ 2.91 1.00 4.00 “ 0.003 S. 
Gestational al delivery (wk) 39.94 ~ 3 7 2 9 ~ 41 .71— 36.16 27.43 0.003 S. 
Final body weight (kg) 63.75 "~50.20 82 .20— 67.99 47.60 82.10 0.241 N.S. 
印 c e n t a l weight (kg) 0.63 ~~0 .50 7 . 5 0 ~ 0.50 0.25 ~ ~ O l O ~ 0.045 S. 
Birth weight (kg) 3.16 ~ 2 . 5 1 3 . 5 5 ~ 2.26 1.01 ~ ~ 3 ! 2 0 ~ 0.012 S. 
Gestational at blood collection (wk) ~ 35.81 39.86 ~ 36.09 一 27.43 39.57 0.184 N.S. 
Haemoglobin (g/dL) 11.49 ~ 0 . 1 0 1 4 . 4 0 ~ 12.35 9.90 0.342 N.S. 
Platelet count (x 10E9/L) 227.89 ~157 .00 2 9 0 . 0 0 ~ 180.82 102.00 ~ 2 5 T 0 0 ~ 0.110 N.S. 
W B C (no. cell/L) 10.46 5.40 20.40 11.61 | 4.9G 20.00 0.515 N.S. 
Normal Pregnant Women Pre-eclamptic yVomen Pearson Chi-Square Test — 
Statistics Proportion % Proportion % p-value (2-tailed)  
Nulliparity 5/11 45.45 5/10 50.00 0.801 I N.S. 
Normal Spontaneous Delievey (NSD) 8/11 72.73 “ 2/11 " I b I F " 0.001 S. 
I Sex of infant (MalB) | 6/10 60.00 7/11 63.64 0.864 N.S. 
Table 5.1. Patient's demographic characteristics and obstetric outcomes for 2D-
PAGE analysis. N.S.: No significance. S.: significance. 
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5.2 Plasma Protein Quantity 
Protein quantifications before and after albumin depletion were shown in Table 
5.2. A hundred jUg albumin depleted plasma protein of gestational age matched 
samples was subjected to 2D-PAGE for comparative analysis. For 11 pairs of 
samples, 83.38 % 士 3 . 0 6 % of protein was removed after albumin depletion. The 
absence of albumin spots indicated the albumin depletion step was successful 
(Figure 5.1). Forty to seventy five [i\ albumin depleted plasma protein constituted 
100 fig total protein was subjected to first dimension separation by lEF. 
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Pair Gestation Cose No. R a w V o l u m e Protein ~ Protein Vol.(ul) 
al age plasma (ill) amount protein conc. for lOOug 
(week) protein for 2500iig after removed (ug/iil) of protein 
conc. nibumiii- albumin- prior to 
(ug/iil) depletion depleted lEF 
(ug) plasiiui in  
Tris buffer  
1 27 1710 48.209 51.858 324.405 87.02 1.622 61.651 
27 711 54.248 46.085 413.916 83.44 2.07 48.319 
2 36 2310 49.202 50.811 362.006 85.52 1.B1 55.248 
36 811 53.907 46.376 279.113 88.84 1.39S 71.656 
3 36 210 46.423 53.853 373.782 85.05 1.438 69.559 
36 3111 52.333 47.771 421.263 83.15 1.62 61.719 
4 37 2610 53.933 46.354 353.597 85.86 1.36 73.53 
37 411 56.207 44.478 377.155 84.91 1.451 68.937 
5 38 3410 54.255 46.078 343.541 86.26 1.321 75.682 
38 1811 52.971 47.196 452.078 81.92 1.739 57.512 
g 39 3510 57.344 43.597 327.807 86.89 1.639 61.011 
39 2111 47.549 52.577 344.867 86.21 1.724 57.993 
1 33 1010 44.273 56.468 423.555 83.06 1.629 61.385 
33 4711 45.701 54.703 479.065 80.84 1.843 54.272 
8 34 1310 55.744 44.848 457.567 81.7 1.76 56.822 
34 4211 53.327 46.881 419.336 83.23 1.613 62.003 
g 36 3910 61.003 40.981 422.365 83.11 1.564 63.926 
36 2011 57.889 43.186 556.473 77.74 2.061 48.52 
10 36 4310 49.75 50.251 442.591 82.3 1.702 58.745 
36 5011 52.592 47.536 505.049 79.8 1.871 53.46 
” 39 4410 48.51 51.536 477.545 80.9 1.837 54.445 
39 I 4111 I 47.894 52.198 584.773 76.61 2.249 44.462 
Table 5.2. Protein quantification before and after albumin depletion. Last digit 




Paired 2D-gels from gestational age matched plasma sample of normal and pre-
eclamptic women were compared. The images of the silver stained 2D-gel were 
acquired with GS-700 Imaging Densitometer (Figure 5.1). The number of spots and 
spot quantities were obtained with the software PDQuest. Two hundred spots were 
indexed and matched across the gel images. 
5.4 SAM analysis 
After normalization of protein spot quantities, the mean intensities of each pair 
in duplicate were subjected to statistical analysis. In total, 200 spots in each 2D-gel 
image were included for analysis. Two spots (Spot # 5204 and Spot # 6210) were 
found to be significant different by SAM. 
Since the plasma sample were gestationally matched, Wilcoxon Signed Ranks 
Test was used to check the difference of normalized spot quantities of Spot # 5204 
and Spot #6210 between the normal pregnant and pre-eclamptic pairs (Table 5.3 
and Table 5.4). The quantity of Spot # 5204 was found statistically lower in pre-
eclamptic group (Z-score = -2.934，p-value = 0.003). The quantity of Spot #6210 




Pair Case Spot # 5204 (X1.00E-03) STDEV (X1.00E-03) 
1 1710 8；^ 24.26 
0711 76 5.10 — 
2 2 3 1 0 — 230 .2 6 .93 ""“"“   
0811 18.8 14.50 — 
3 0 2 1 0 — 122.9 — 33 .57 — 
3111 65 .5 4 .84 — 
4 2 6 1 0 — 131.9 — 15.62 ~ ~  
0411 49 .2 27 .87 — 
5 3410 — 81.9 — 10.42 
1811 — 70 — 7.74 
g 3510 140.9 — 3 .08 
2111 51 .3 11.17 — 
7 1010 — 54.2 — 13.33 — 
4711 17.6 4 .04 — 
g 1310 174.1 62 .09 
4211 — 136.1 — 31 .42 一 
9 3 9 1 0 — 194.2 — 10.96 
2011 65 .3 一 23 .52 
10 4 3 1 0 141.3 — 13.45 — 
5011 27 .5 5 .92 
” 4 4 1 0 — 166.5 — 5.61 ~ ~  
4111 115.8 2 1 . 4 5 
Table 5.3. Normalized spot quantities of Spot # 5204. For Wilcoxon Signed 
Ranks Test, samples were gestationally matched as indicated. 
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Mean quantity 
Pair Case Spot # 6210 (X1.00E-03) STDEV (X1.00E-03) 
^ 1710 — 39.4 3.58 
0711 — 3.6 1.84 — 
2 2310 — 70.6 30.72 
0 8 1 1 — 0.1 — 0 .01 
3 0210 — 7.7 一 5.74 — 
3111 1.6 1.67 — 
~ 2610 — 17.2 1.19 
0411 5.5 2.09 — 
~ 3410 22 5.77 
1811 — 1.9 一 1.48 — 
g 3510 6.1 — 0.69 — 
2111 4.7 0.95 — 
1010 4.2 — 4.06 
4711 1 2.31 — 
~ 1310 — 39 — 0.18 
4211 一 5.6 一 3.25 — 
g 3910 6.3 — 6.94 
2011 0.1 0.15 一 
10 4310 — 40 ~ 0.27 
5011 5.4 — 0.87 — 
” 4410 — 10.4 — 2.46 
4111 5.1 0.14 
Table 5.4. Normalized spot quantities of Spot #6210. For Wilcoxon Signed 
Ranks Test, samples were gestationally matched as indicated. 
49 
5.5 Spot # 5204 and Spot # 6210 
Figure 5.1 shows representative 2D-gel images of a pair of gestational age 
matched plasma protein samples name 3910 and 2011. 3910 is a normal plasma 
protein sample, 2011 is a pre-eclamptic plasma protein sample. Spot # 5204 situated 
at the centre of the Gel #3910 and Gel # 2011，with an experimental isoelectric 
point (pi) value of 6.04 and an experimental molecular weight (M.W.) of 33.1 KDa. 
Spot #6210 situated near the centre of the Gel # 3910 and Gel #2011 with an 
experimental isoelectric point (pi) value of 6.25 and an experimental molecular 
weight (M.W.) of 34.3 KDa. 
Figure 5.2 and Figure 5.3 showed Spot # 5204 and Spot # 6210 in 11 pairs 
gestational age matched samples in duplicate, respectively. The spot quantities of 














































































































































































































































































































































































































G e s t a t i o n a l A g e M a t c h e d 
N o r m a l P r e g n a n c y P r e - e c l a m p s i a 
G e s t a t i o n a l A g e 
(wk) dupl icate 1 dupl icate 2 dupl icate 1 dupl icate 2 
• • # 修 
1710-1 1710-2 0711-1 0711-2 
參 、 , # 
3 3 1010-1 1010-2 4711-1 4711-2 
• • • -
^ 1310-1 1310-2 4211-1 4211-2 
一 
站 2310-1 2310-2 0811-1 0811-2 
3 6 0210-1 0210-2 3111-1 3111-2 
. m 參 
3 6 3910-1 3910-2 2 0 1 M 2011-2 
3 6 4310-1 4310-2 5011-1 5011-2 
3 7 2610-1 2610-2 0411-1 0411-2 
3 8 3410-1 3410-2 1811-1 1811-2 
• ‘ • SI' 
3 9 3510-1 3510-2 2111-1 2111-2 
3 9 4410-1 4410-2 4111-1 4111-2 
Figure 5.2. Spot # 5204 in 11 pairs of 2D-gels. The samples were gestational 
age matched and arranged horizontally. 
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Gestat iona l A g e M a t c h e d 
Norma丨 P r e g n a n c y P r e - e c l a m p s i a 
Gesta t iona l A g e 
(wk) duplicate 1 duplicate 2 duplicate 1 duplicate 2 
1710-1 1710-2 0711-1 0711-2 
3 3 1010-1 1010-2 4711-1 4711-2 
拟 1310-1 1310-2 4211-1 4211-2 
3 6 2310-1 2310-2 0 8 1 M 0811-2 
J p 
36 0210-1 0210-2 3111-1 3111-2 
36 3910-1 3910-2 2011-1 2011-2 
-‘i ‘ • 
3 6 4310-1 4310-2 . 5011-1 5011-2 
a" 
3 7 2610-1 2610-2 0411-1 0411-2 
‘ V . 
3 8 3410-1 3410-2 1811-1 1811-2 
39 3510-1 3510-2 2111-1 2111-2 
• # 
39 4410-1 4410-2 4111-1 4111-2 
Figure 5.3. Spot # 6210 in 11 pairs of 2D-gels. The samples were gestational 
age matched and arranged horizontally. 
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5.6 Protein Identification 
5.6.1 Identification of Protein Spot # 5204 
From the peptide mass spectrum of Spot # 5204 (Figure 5.4)，peptide mass list 
(Table 5.5) was subjected to database search by Profound. Input summary showed 
the monoisotopic masses of peptide entered and the criteria chosen for the optimum 
database search. 
4 7 0 0 M S S p o t # 5 2 0 4 S p e c 
in 
， ^ T796.3 
90. S E s 
I ^ S 
80 I ？ S 
70 
盆 6 0 . 资 
c o tn 
I 60 " a? § 
� " j I i 
- , I i N n i s i ' 
- f f i j i f 囊 } 
._ l i i i l l . . JL . i i l l i j . . _ i d j _ I  
ra 1166 1601 1837 2173 2509 Mass (m/z) 
Figure 5.4. Peptide mass spectrum of Spot # 5204 
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D a t a b a s e NCBInr (2005/03/01) 
Taxonomy Category Homo sapiens ( h u m a n ) ^ H H B B M M M I I I i l i m t 
Protein Mass Range 0 -100 
Protein pi Range T H � , n # ^ B B B H I I i m H i i i l i l i i l P 
Search for Single protein 
Digest Chemistry " $ Trypsin , 德 g ^ ^ E H ^ H B H I P 
Max Missed Cut — 1 
Modifications ‘? 
Charge State MH+ ~ 
Peptide Masses 968.5570 982.5740 992.5980 1024.4608 1051.6680 
(Da, Monoisotopic) 1053.4560 1069.4945 1070.4790 1113.5245 1147.4840 
1163.5013 1166.5960 1178.5730 1182.5920 1225.5730 
1226.5702 1310.6000 1555.8387 1620.7670 1864.9050 
Tolerance (MON) . 0.0—5 
Number of Peptides 20 • - ^ ^ T M H P i l i i i W M B W f c ‘ 
Table 5.5. Input summary of Spot # 5204 showing the monoisotopic mass 
of peptides entered and the criteria chosen for the Profound database 
search. 
From the Profound search result summary (Table 5.6) and search result details 
(Table 5.7), Spot # 5204 was identified to be H-ficolin with a theoretical pi value of 
6.2 and a molecular weight of 32.89 kDa. These search results matched the 
experimental molecular weight and pi value of Spot #5204 in 2D-PAGE. 
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, Version 4.10.5 
r r o r OUna - Search Result Summary The Rockefeller university Edition 
I gi|27754776lref1NP 003656.2| ficolin 3 
isoform 1 precursor; ficolin-3; 
collagen/fibrinogen domain-containing lectin 
+ 1 l.Oe+000 1.69 3 p35; collagen/fibrinogen domain- 18 6.2 32.89 
containing protein 3; Hakata antigen; H-
ficolin; ficolin (collagen/fibrinogen domain-
containing) 3 (Hakata antigen) [Homo 
sapiens] • 
+2 3.4e-005 ^ 0.22 I M|3342236|gb|AAC39917.1| glycine J 9.1 51.95 
rprftntnr alpha 3 suDunit [Homo sapiens] ^ ^ 
. 3 ？7e oi?7 "？? ' p 3 0 3 5 4 4 8 8 | g b | A A H 5 2 3 1 0 . 1 | TXNDC5 ^ 5.6 40.35 
[protein [Homo sapiens] 一. 一 
I gi|21166361lref]NP 115758.2| component 
4 8.5e-008 - of oligomeric golgi complex 8; dependent on 8 j�5.2 68.43 
RJCl [Homo s a p i e n s ] ]丨“丨丨丨丨丨丨；丨•丨•麵 
+ 5 1 9e-008 - i ; S ^ 4 S ; j g b | A A“； & . : i | S n ^ ^ o S M — ^ ^ 45.31 
R ^ S ^ protein [ H o m o ^ s a p i e n s ] 一 — 
6 1 4 e - o P _ - I gi|7959712g|AAF71Q29.1| PR00412 g 6.9 62.05 
[Homo sapiens]  
+7 1 3e.008 ' ' ' - Igi|10436048|dbi|BAB14737.1| unnamed ^ 4 0 20.98 
. protein product [Homo sapiens] 
I gi|21284387lref1NP 006711.21 actin-
+ 8 Lle-008 - binding LIMprotein 1 isoform s; actin- 9 8.6 52.66 
binding LIM protein; LIM actin-binding 
protein 1 [Homo sapiens] 
+ 9 4 3e-009 - r i ^ i | 1 4 0 4 3 ^ b | A A H 0 7 m i i EIF2C2 ^ 9.6 42.36 
proteiiyHom^apiens] 忍 ,稱 
+ 10 4 ie_009 - | I _ 6 ? 3 5 8 4 |寻A A F 2 2 7 9 9 , | AXIN2 5 ；.5 86.84 
• 丨丨[Homo sapiens] 一 
Table 5.6. Profound search result summary of Spot # 5204 showing the 
ranking, the probability and Z score of the protein identity. 
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^ J Version 4.10.5 
P r O r o u n u — The Rockefeller 
University Edition 
Search Result Details of Spot # 5204 
gj127754776IreflNP 003p6 . 2 l ficolin 3 isoform 1 pre^rsor: ficolm-3: 
collagen/fibrinogen domain-containing lectin 3 p35; collagen/fibriTiogen domain-
containing protein 3: Hakata antigen: H-ficolin: ficolin (collagen/fibrinogen domain-
containing) 3 CHakata antigen) rHomo sapiens"! 
" I •‘ • - _ ''" _ • 一 ’ 二 一 "H" “ • _ ‘ - - - 1 i i^-^I tUyTj . I—. 
Measured peptides ： 20 
Min. sequence coverage: 18% J H ^ K ^ I ^ ^ ^ ^ ^ 
, • . C O V E R A G E HftP flND ERROR MAP ' ^ B B I P l i ‘ ‘ • f 
900 • ikwtofll.O . 0 +o'o2- | 
： • . •； . . v R E S I D U E NUMBER .^ •； E R R ( D f l ) . - g 
1023.458 M 1023.477 -0.019 277 285 0 Y G I D W A S G R 
1069.471 M 1069.482 -0.011 137 145 0 Q D G S V D F F R n 
1112.523 M 1112.540 -0.017 191 199 0 TFAHYATFR 
1165.588 M 1165.609 -0.021 75 85 0 G E P G D P V N L L R 
1225.569 M 1225.584 -0.014 136 145 1 R Q D G S V D F F R 
1554.839 M 1554.840 -0.001 200 213 0 LLGEVDHYQLALGK 
Table 5.7. Profound search result showing the identity of Spot # 5204, the 
coverage map of matched peptides sequence to the whole protein sequence 
and the identities of the matched peptides. The peptide mass shown here is 
the average mass in default by the search engine. Though the average mass is 
shown here, it refers to the same peptides mass in the input. 
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The six most intense peptides from the peptide mass list of Spot # 5204 were 
selected and subjected to further peptide fragmentation analysis by collision-induced 
dissociation to obtain the amino acid sequence information. Peptide fragment mass 
spectrum of three out of six peptides were successfully obtained (Figure 5.5 -
Figure 5.7). The peptide fragment mass spectrum results were then subjected to 
database search by MS/MS Ion Search of Mascot (Figure 5.8). The sequence of 
peptide 1070.50 kDa was identified to be QDGSVDFFR. The sequence of peptide 
1226.59 kDa was identified to be RQDGSVDFFR. The sequence of peptide 
1555.84 kDa was identified to be LLGEVDHYQLALGK. All three peptides 
sequences matched to that of protein H-ficolin. As a result, Spot # 5204 is H-ficolin 
(FCN3; accession CAI14774; 299AA). 
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Figure 5.5, Peptide fragment mass spectrum of peptide 1070.479 KDa 
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Figure 5.6. Peptide fragment mass spectrum of peptide 1226.59 KDa 
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Figure 5.7. Peptide fragment mass spectrum of peptide 1555.847 KDa 
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fMATlUXl 
I SCIENCE J Mascot Search Results 
Database : MSDB 20050227 (1942918 sequences; 629040812 residues) 
Taxonomy : Homo sapiens (human) (130772 sequences) 
Significant hits: Q5SSB9_HUMAN Ficolin (Collagen/fibrinogen domain containing) 3 
(Hakata antigen).- Homo sapiens (Human). 
Probability Based Mowse Score 
Ions score is -10*Log(P), where P is the probability that the observed match is 
a random event. 
Individual ions scores > 32 indicate identity or extensive homology (p<0.05). 
Protein scores are derived from ions scores as a non-probabilistic basis for 
ranking protein hits. 
Rank. 1 
05SSB9 HUMAN 
Ficolin (Collagen/fibrinogen domain containing 3 (Hakata antigen). - Homo sapiens (Human). 
Score: 136 
Queries matehed: 3 
Qmety Obseived Mr(eayt) Mr(cak) Delta Miss Score Bqpect Rank Peptide  
1 107030 1069.49 1069.48 丨 QjQl 丨 0 ^ 16 2.7 1 ^ QDGSVDFFR 
2 1226^0 1225^9 122558 0J)0 1 54 0J00048： 1 . RQDGSWFFR 
3 1555.84 1554.83 1554^4 -0.01 0 66 15e-05 1 LLGEVDHY(?LALGK 
Figure 5.8. Mascot Search Results showing that the precursor ions from 
Spot # 5204 emerge to the same protein, H-ficolin (ficolin 3). Query 1，2 
and 3 are the search of the 3 peptides of interest. Score > 32 indicates 
identity or extensive homology (p<0.05). 
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The monoisotopic mass appear in the peptide mass spectrum results (Figure 5.4) 
is a little bit different from the mass of the precursor ions in the fragment mass 
spectrum (Figure 5.5 - Figure 5.7). This was because they were generated form two 
separated experiment with slight differences due to calibration. 
5.6.2 Identification of Protein Spot # 6210 
From the peptide mass spectrum of Spot #6210 (Figure 5.9), peptide mass list 
(Table 5.8) was subjected to database search by Profound. Input summary showed 
the monoisotopic masses of peptide entered and the criteria chosen for the optimum 
database search. 
TO 4700 M S S p o t # 6 2 1 0 S p e c 
<jt 
S 5 
100-, “ g 4.3E+4 
90 ？ 。 
80 “ 
70 
I ~ I 
I ： 3 SS S 
lO 
30 i g 
： l i i i i i I ^ I 
18270 1509.4 1750.6 1991.8 
Mas  (mJz) 
Figure 5.9. Peptide mass spectrum of Spot # 6210 
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Database NCBlnr (2005/05/01) 
Taxonomy Category Homo sapiens (human� 
Protein Mass Range 10-50 kPa . S ^ B M B M i m i m H 
Protein pi Range 3^ 0 -10.0 ._^^1^1；^^^^|||||||||1|1[|_||丨111111 
Search sTngle 
Digest Chemi^y- j i h fi^n ^ ^ M H U B B m i m i U B S 
Max Missed Cut 丨!J . 
Charge State MH+ j p g ^ p ^ m ^ f ^ ^ p ^ f ^ g ：: • 
Peptide Masses _ 1039.548 T S . 4 5 6 lOSxSSs 1067.597 1073.531 
(Da, Monoisotopic) 1111.538 1123.552 1127.5321169.562 1170.555 培,:：,:臺 
1171.534 1185.610 1195.582 1211.566 1213.590 寐丨饭 
1227.581 1229.574 1279.585 1285.600 1286.659 •‘ • ；4:1 
1388.624 1389.638 1448.635 1702.800 2041.997 ••.•'i；'；^；-'^ -^' 
-」2043.958 2058.948 . ： ‘ . : .力献纖 
Tolerance (MON) 二 
Number of Peptides 「： y | T T t i t i i i H i l l H | | t l | | l i l B I B I I I I I I I i W M ^ 
Table 5.8. Input summary of Spot # 6210 showing the monoisotopic mass 
of peptides entered and the criteria chosen for the Profound database 
search. 
From the Profound search result summary (Table 5.9.) and search result details 
(Table 5.10.), Spot #6210 was identified to be L-ficolin with a theoretical pi value 
of 6.09 and a molecular weight of 34.02 kDa. These search results matched the 
experimental molecular weight and pi value of Spot # 6210 in 2D-PAGE. 
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^ ^ - Version 4.10.5 
" r o r Olincl - Search Result Summary The Rockefeller university Edition 
Tgil8051586lreflNP 056652.11 ficolin 2 
isoform b precursor; ficolin 
+1 l.Oe+OOO 0.86 fcolla^n/^ibrlno^ndom^n^ontaining 红 5.9 30.21 
lectin) 2; ficolin (coUagen/fibnnogen domain-
containing lectin) 2 (hucolin); hucolin [Homo 
sapiens] 
Tgil21389439lreflNP 653225.11 kinase 
+2 LOe-003 - interacting stathmin; KIS protein kinase 12 5.5 38.10 
[HonK) sapiens] 
TgijS292956lmrllT51874 hypothetical protein ^ 8 4 4 3 1 8 
3 ^ DKFZp762P233^uman (fragment) — . . 
4 4 6e-004 I 一 %丨 5 5 7 7 9 7 2丨 g ^ 5 4 0 5 . 1 l cytochrome ” ^ ^ 45,明 
穩 P450 21-hydroxyl_ase [Homo sapiens] — 
5 _ TRil22760360ldbilBAC11166.ll unnamed 22 8.0 27.31 
• • protein product [Homo sapiens] 
Tgill4149849lreflNP 115543.11 hypothetical 1 0 5 6 4134 
6 1-86-004 - protein FLJ12363 [Homo sapiens] 一 . . 
•SE B——""iHlli"lillff"- :-UIIII!!ll[I^ LIllllLIWim^  ‘ . • 
7 7 le-005 - TRil7717243lemblCAB9Q395.1IPRED65 边 9.5 46.03 
‘ [Homo sapiens] 
Tgilll641279lreflNP 071755.11 human 
epididymis-specific 3 beta precursor; human 
8 5.6e-005 - epididymis-specific 3 beta; epididymal 19 6.5 17.57 
secretory protein E3 beta precursor [Homo 
sapiens] 
… Tgill 136001 llpirllT46468 hypothetical protein �锁 
9 4.9e-005 - DKFZP434G1130.1-human (fragment) 1 ^ 5 . 0 2 . 8 8 
A: Tgill6506299lreflNP 443172.11 hypothetical ” 
1 0 4 . 7 e - 0 0 5 - , . 八 許 o n … r t j “ V 1 3 7 . 3 4 8 . 5 5 
protein MGC8974 [Homo sapiens] 
Table 5.9. Profound search result summary of Spot #6210 shown the 
ranking, the probability and Z score of the protein identity 
63 
^ „ , Version 4.10.5 
P r O r o u n c l — The Rockefeller 
汽一 . . ^ ^ . ^ University Edition 
Search Result Details of Spot #6210 
gil8051586lreflNP_056652.1 Ificolin 2 isoform b precursor; ficolin (collagen/fibrinogen domain-
containing lectin) 2; ficolin (collagen/fibrinogen domain-containing lectin) 2 (hucolin); hucolin 
[Homo sapiens] ^ S S s s ^ S ^ H I ^ B S ^ ^ S i 
Measured p e p t i d e s : 27 
Min' LqSen^e 二verage 
……—-——===~ .MiBlliniifeBliiipaHiaBpaiiii^^    
COVERAGE MftP-ftND TERROR MftP i ^ W B W p 別 
BDATA I- UN-MODIFIED ~ ~ ^ T ^ B 
-MATCH 1-； ： 
iooo ‘ ‘ 2100DP 0 ‘ . . 0 +0.06 ；, . ..RESIDUE： NUMBER - 二 E R R < D A > ‘ 
. . . . • . �...r. I ,r I - H, 丨一“ * ! • “ - - _ - -H _•-•_ •丨•••一 . - -—I . .、 . . _“•. '-'I • .-. • • • • • ••‘{••ip 
1056.485 M 1056.487 -0 .002 111 119 0 VDGSVDFYR 
1122.544 M 1122.555 -0 .011 171 180 1 SFKVADEAEK 
1169 547 M 1169.536 0 .012 231 240 0 NCHVSNLNGR (l)+C2H30N(C; 
1212.582 M 1212.588 -0 .006 110 119 1 RVDGSVDFYR 
1387.616 M 1387.663 -0 .047 244 256 0 GTHGSFANGINWK 
1701.792 M 1701.788 0 .004 155 168 0 VDLVDFEDNYQFAK 
Table 5.10. Profound search result showing the identity of Spot # 6210, the 
coverage map of matched peptides sequence to the whole protein sequence 
and the identities of the matched peptides. The peptide mass shown here is 
the average mass in default by the search engine. Though the average mass 
is shown here, it refers to the same peptides mass in the input. 
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Six most intense peptides from peptide mass list of Spot #6210 were selected 
and subjected to peptide fragmentation analysis by collision-induced dissociation to 
obtain the amino acid sequence information. Peptide fragment mass spectrum of 
three out of six peptides were successfully obtained. The peptide fragment mass 
spectrum results (Figure 5.10 - Figure 5.12) were then subjected to database search 
by MS/MS Ion Search of Mascot (Figure 5.13). The sequence of peptide 1702.80 
kDa was identified to be VDLVDFEDNYQFAK. The sequence of peptide 
1213.59 kDa was identified to be RVDGSVDFYR. The sequence of peptide 
1057.49 kDa was identified to be VDGSVDFYR. All three partial sequences came 
from the same protein L-ficolin. As a result, Spot # 6210 is L-ficolin (FCN2; 
accession no. gi|1669349; 313AA). 
4 7 0 0 M S / M S P r e c u r s o r 1 7 0 2 . 8 S p e c 
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Figure 5.10. Peptide fragment mass spectrum of peptide 1702.80 KDa 
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Figure 5.11. Peptide fragment mass spectrum of peptide 1213.50 KDa 
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Figure 5.12. Peptide fragment mass spectrum of peptide 1057.49 KDa 
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fMATKIXl 
^science/Mascot Search Results 
Database : NCBInr 20050516 (2464940 sequences; 834614836 residues) 
Taxonomy : Homo sapiens (human) (134579 sequences) 
Significant hits: gi|1669349 lectin P35 [Homo sapiens] 
Probability Based Mowse Score 
Ions score is -10*Log(P), where P is the probability that the observed match is 
a random event. 
Individual ions scores > 47 indicate identity or extensive homology (p<0.05). 
Protein scores are derived from ions scores as a non-probabilistic basis for 
ranking protein hits. 
Rank. 1 
g i l l 6 6 9 3 4 9 
lectin P35 [Homo sapiens] 
Score: 118 
Queries matched: 3 
Query Observed Mr (expt )iMr(calc) Delta Miss Score Expect Rank Peptide  
i 1057,49 1056,48 | 1056,49 -0 .01 ,.…0 ：.....22 , 17 1 ..j TOGSTOFYR 
z 1 2 1 3 1 9 1212.59 ‘ 1212.59 -0 .00 1 27 4 丄 ― 刚 G S V D l ^ X ! ^ — 
3 l ? ^ ? ? ? 1701.77 1701.79 -0 .02 0 70 0.00035 1 VDLVDFEDHYQFAX 
Figure 5.13. Mascot Search Results showing that the precursor ions from 
Spot #6210 emerge to the same protein, L-ficolin (Lectin p35).Query 1，2 
and 3 are the search of the 3 peptides of interest. Score > 47 indicates 
identity or extensive homology (p<0.05) 
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5.7 Patients' Demographic Characteristics and Obstetric 
Outcomes for Immunoassays 
The patients' demographic characteristics and obstetric outcomes for 
immunoassays were summarized in Table 5.11. There was no significant difference 
in maternal height, gravidity, final body weight, gestation at blood collection, 
haemoglobin, platelet count, white blood cell count (WBC)，urea, creatinine, 
alkaline phosphatase (ALP), nulliparity and sex of infant between normal pregnant 
women and pre-eclamptic women. Age, body weight before pregnancy, maximum 
systolic blood pressure at delivery (Max sbp), maximum diastolic blood pressure at 
delivery (Max dbp), proteinuria and serum urate were significantly lower in normal 
pregnant women. Gestation at delivery, birth weight, platelet count, total protein, 
albumin (ALB) and normal spontaneously delivery were significantly higher in 
normal pregnant women. 
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Normal Pregnant Women Pre-eclamptic W o m e n Mann-Whitney U Test 
Number of cases 45 20 p-value (2-tailBd) 
Mean Minimum I Maximum Mean Minimum Maximum p-value 
Age (years old) 29.79 " T 1 . O O 39.00 32.56 “ 18.00 0.027 S . — 
Maternal height (cm) 156.43 "T1O.OO 174 .00~ 158.49 149.50 167.00 0.387 M.S. ~ 
Body weight before p r e q n a n c Y (kg) “ 52.30 ~ 3 3 . 9 D 72 .00— 59.11 41.00 74.80 0 .027 S. 
Gravidity 2.05 ~ T 0 0 ~ 6.00 — 2.47 1.00 5.00 0 .207 M.S. 
Max sbp (mmHg) 123.65 ~ 0 1 . 0 0 1 7 9 . 5 6 ~ 160.00 210.00 0 .000 S. 
Max dbp (mmHq) 73.84 ~ 6 4 . 0 0 97.00 1C36.94~ 80.00 125.00 0 .000 S. 
Proteinuria (no. of positiva sign) ~ 0.00 1.00 2 . 6 9 ~ 0.00 4.00 0 .000 S. 
Gestational at delivery (wk) 39.46 34.00 41.71 35.74 27.57 39.57 0 .000 S. 
Final body weight (kg) — 6 6 . 4 9 86.00 £9.98 47.60 85.20 0 .205 M.S. 
Placental weight (kg) 0.54 ~ T 3 i ~ 0.75 “ 0 .52 0 .25 O.BS 0.351 M.S. 
Birth weight (kg) 3.14 2.27 3.75 2.34 1.01 3.91 0.001 S. 
Gestational at blood collection (wk) 34.60 27.29 39.86 35.34 27.43 39.29 0 .363 M.S. 
Haemoglobin (g/dL) — 11.90 9.00 14.40 11.44 8.70 14.30 0 .355 N.5 . 
Platelet count (x 10E9/L) 249.48 157.00 420.00 198.19 102.00 279.00 0 .018 S. 
W B C (no. cell/L) 12.65 20.60 11.31 4.90 20.00 0.464 M.S. 
Serum ALT (lU/L) 34.00 19.13 10.00 44.00 0.441 N.S. 
serum urate (mmol) 0 .30 " ~ a 2 i ~ 0.30 0 .45 0.25 0 .60 0 .018 S. 
Urea (mmol) 4.04 2.30 5 .60 4.68 2.20 6 .10 0.264 N.S. 
Creatinine (umol) — 64.60 ~ " 5 0 0 ^ 82.00 68.75 49.00 84.00 0.45S N.S. 
Total protein (g/L) 70.40 61.00 81.00 63.25 52.00 74.00 0 .042 S. 
ALB (g/L) 35.40 " T T o o T 45.00 28.81 21.00 36.00 0 .009 S. 
A L P (lU/L) 152.00 77.00 219.00 164.63 88.00 287.00 0.741 N . S . — 
Normal Pregnant W o m e n Pre-eclamptic W o m e n Pearson Chi-Square Test 
Statistics Proportion % Proportion % p-value (2-tailed) 
Nulliparity 22/36 61.11 6/15 40 0.121 N.S. 一 
Normal Spontaneous Delievev (NSD) 29/36 60.56 12.5 0.001 S. 
^ x of infant (Male) 丨 19/37 51.35 9 /16 56.25 0 .743 N.S. 
Table 5.11. Patient's demographic characteristics and obstetric outcomes for 
immunoassays. N.S.: No significance. S.: Significance. 
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5.8 Immunoassays 
To confirm that the levels of H-ficolin and L-ficolin were lower in plasma of 
pre-eclamptic women, ELISA was performed. Since mannose-binding lectin (MBL) 
shares similar domains and function with H-ficolin and L-ficolin, the plasma 
concentrations of MBL were also measured by ELISA method. Three sandwich 
ELISAs for H-ficolin, L-ficolin and MBL were performed independently. 
For H-ficolin, a PSA based ELISA was adopted according to Tsujimura et al 
described (Tsujimura et al., 2001). PSA was used as the capturing agent. Mouse 
anti-H-ficolin was used as the detecting antibody. PSA is the polysaccharide capsule 
structure purified from Aerococcus viridans with very high affinity to H-ficolin 
(Tsujimura et al., 2001). This immunoassay was adopted since there is only one 
clone of monoclonal anti-H-ficolin commercially available; other attempts such as 
direct ELISA or sandwich ELISA using anti-H-ficolin and DIG-labeled anti-H-
ficolin failed. H-ficolin exists as a polymer comprising multiple identical monomers. 
There should be multiple identical epitopes for the same monoclonal anti-H-ficolin 
for binding. It seems that there was inactivation of antibody during the DIG-labeling 
process, however. Also, there is 0.1% albumin in anti-H-ficolin preparation. The 
albumin present might prevent anti-H-ficolin from coating onto the well and act as 
capturing antibody (see appendix for detail protocols). 
For L-ficolin, mouse monoclonal anti-L-ficolin was used as the capturing 
antibody and rabbit polyclonal anti-L-ficolin was used as the detecting antibody. For 
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MBL, anti-MBL-ficolin was used as the capturing antibody and DIG-labeled anti-
MBL-ficolin was used as the detecting antibody. MBL exists as a polymer 
comprising multiple identical monomers. There are multiple identical epitopes for 
the same monoclonal anti-MBL-ficolin for binding. These proteins were then 
quantitated by measuring the amount of sandwich antibody- antigen complexes 
through the use of a horseradish peroxidase conjugated antibody and colorimetric 
substrate. 
Concentrations of plasma H-ficolin, L-ficolin and MBL were measured in 45 
normal pregnant women and 20 pre-eclamptic women collected separately from 
proteomic analysis. Their gestational week ranged from 27 to 39. Concentrations of 
H-ficolin, L-ficolin and MBL are shown in Table 5.12. Concentrations ofH-ficolin, 
L-ficolin and MBL in normal pregnancy were plotted against gestational week 
(Figure 5.14 - Figure 5.16). By non-parametric Spearman's correlation test, in 
normal pregnant women, there were no significant correlations between the 
concentrations of respective proteins to gestational age. 
71 
Descript ive H-ficolin (n(|/ml) L-ficolin (ngin l ) MBL (^g/ml) 
I 二 丨 二 e N o r m a l f ~ ^ N o r m a l f ~ ~ P ^ - N o r m a l P ie -
‘ Pregnancy eclampsia Pregnancy eclampsia Pregnancy eclampsia 
N u m b e r 
of Case 45 ^ 45 ^ j 5 20 
— M e a n 15.245 7.612 16.53 5.704 23.667 24.694 
M e d i a n 11.986 8.19 13.191 5.137 21.378 16.331 
Std. 
Dev ia t ion 11.765 3.269 9.599 2.113 15.46 20.44 
lO .e i^ 92.138 4.463 239.006 417.814 
_ _ 1 4 . 5 9 44.442 8.5G8 63.886 69.931 
M i n i m u i i T 1.39 0.77 4.696 2.71 2.148 3.786 
M a x i i m m i 61.06 15.37 49.138 11.278 66.034 73.717 
Percent i les  
25th 9.296 6.252 9.094 4.078 8.916 8.154 
50th 11.986 8.19 — 13.191 5.137 21.378 16.331 
一75th ~ r 4 . 8 6 8 9.525 24.294 6.701 34.831 44.058 
Table 5.12. Concentrations ofH-ficolin, L-ficolin and MBL in normal 
pregnancy and pre-eclampsia. 
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Concentration of Plasma H-ficolin in 
Normal Pregnant Women 
70 -] 
6 0 - • 
• i “ Regression line 
3, y = -0.4136x +29 .427 
c 4 0 - • % R2 = 0.013 
i 30 . Spearman's correlation 
S • • • Correlation coefficient= -0.098 
c • p-value (2-tailed)= 0.524 
、 ： r ^ ^ T T r n T r 
0 J , 1——^  
25 30 35 40 
Gestational W e e k 
Figure 5.14. Concentration of plasma H-ficolin in normal pregnant women 
plots against gestational week. N=45. There was no significant correlation 
between the concentrations of plasma H-ficolin in normal pregnancy and 
gestational age. 
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Concent ra t ion of P lasma L-f icolin in 
Normal Pregnant W o m e n 
60 -] 
50 - • 
一 Regression line 
f y = -0 .5682x + 3 6 . 0 1 3 
CT R2 = 0 .0369 
晋 • 
o ^ • Spearman's correlation 
"I ‘ • • Correlation coefficient= -0.201 
专 • • • J • p-value (2-tailed)= 0.185 
0 • • 
1 20- • • • 
• 拿 
0 J    
25 30 35 40 
G e s t a t i o n a l W e e k 
Figure 5.15. Concentration of plasma L-ficolin in normal pregnant women 
plots against gestational week. N=45.There was no significant correlation 
between the concentrations of plasma L-ficolin in normal pregnancy and 
gestational age. 
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Concent ra t ion of P lasma M B L in 
Normal Pregnant W o m e n 




50 - • 
® • • • Regression line 
_ 4 0 - y = 0.8108x - 4.1335 
0 畚 • • • • R^ = 0.029 
••5 • 2 • • 
30 - • • Spearman's correlation 
8 • • — ^ Correlation coefficient= 0.193 
1 • p-value (2-tailed)= 0.203 
O 20- ^ • • • 
• 
10- • • • • • • • 
t • • ••拿 
• • 
0 -I i— ‘ 
25 30 35 40 
Gestational Week 
Figure 5.16. Concentration of plasma MBL in normal pregnant women 
plots against gestational week. N=45.There was no significant correlation 
between the concentrations of plasma MBL in normal pregnancy and 
gestational age. 
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The scatter plots and the boxplots of H-ficolin, L-ficolin and MBL in normal 
pregnancy and pre-eclampsia were shown in Figure 5.17 - Figure 5.19. 
Concentrations of plasma H-ficolin, L-ficolin and MBL in 45 normal control and 20 
pre-eclamptic women were subjected to Mann-Whitney U Test, a non-parametric 
rank sum test to check the difference between the groups. Concentrations of plasma 
H-ficolin and L-ficolin in pre-eclamptic women were significantly lower than in 
normal pregnant women and there was no difference for MBL. 
Diagnostic values of these proteins in pre-eclamptic women were examined by 
measuring the area under the ROC curve. For concentration of plasma H-ficolin, 
area under the ROC curve = 0.786 (p-value = 0.0001 and standard error = 0.058). If 
the concentration of 9.02 ug/ml of plasma H-ficolin was used as the cutoff value to 
distinguish pre-eclampsia from normal pregnant, it resulted a sensitivity of 70% and 
a specificity of 80%. 
For concentration of plasma L-ficolin, area under the ROC curve = 0.926 (p-
value = 0.0001 and standard error = 0.031). If the concentration of 7.13 pg/ml of 
plasma L-ficolin was used as the cutoff value to distinguish pre-eclampsia from 
normal pregnant, it resulted a sensitivity of 80% and a specificity of 89%. 
Concentration of plasma L-ficolin would be considered as a better biomarker for 
distinguishing pre-eclampsia from normal pregnancy (Figure 5.20). 
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Concentrat ion of Plasma H-ficolin in 
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Figure 5.17. Scatter plot and boxplot of the concentrations of plasma H-
ficolin in normal pregnancy and pre-eclampsia. Concentration of plasma H-
ficolin in pre-eclamptic women was significantly lower than that in normal 
pregnant women. 
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C o n c e n t r a t i o n o f P l a s m a L- f ico l in in 
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Figure 5.18. Scatter plot and boxplot of the concentrations of plasma L-
ficolin in normal pregnancy and pre-eclampsia. Concentration of plasma L-
ficolin in pre-eclamptic women was significantly lower than that in normal 
pregnant women. 
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Concent ra t ion of Plasma Mannose Binding Lectin 
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Figure 5.19. Scatter plot and boxplot of the concentrations of plasma 
Mannose Binding Lectin (MBL) in normal pregnancy and pre-eclampsia. 
Concentrations of plasma MBL in pre-eclamptic women was not significantly 
different from that in normal pregnant women. 
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Figure 5.20. ROC curve of L-ficolin, H-ficolin and MBL with area 
under the curve 
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Chapter 6 Discussion 
H-ficolin, L-ficolin and mannose-binding protein (MBL) belong to the lectin 
family and play an important role in innate immunity. They are plasma proteins 
which act as pattern recognition receptors of a wide spectrums of pathogens and 
elicit complement activation through the lectin pathway (Matsushita & Fujita, 2001). 
Their plasma levels were found to be associated with various immunodeficiency 
diseases. H-ficolin was first identified as a serum antigen recognized by an 
autoantibody present in patients with systemic lupus erythematosus (SLE) (Inaba & 
Okochi, 1978). L-ficolin insufficiency is associated with recurrent respiratory 
infections in childhood (Atkinson et al., 2004). Low MBL levels, may be a risk 
factor for severe malaria in some young children who lack well-developed, clinically 
protective acquired immune responses (Luty et al, 1998). MBL deficiency is also 
associated with recurrent miscarriage (Kilpatrick et al., 1995). 
From the ELISA results, concentrations of plasma H-ficolin and L-ficolin were 
found to be significantly lower in pre-eclampsia than in normal pregnancy. 
Concentration of plasma MBL was found to be no difference between the two 
groups. There has no literatures reporting the relationship between pre-eclampsia 
and ficolins. The roles of ficolins in normal pregnancy and in pre-eclamptic 
pregnancy are not clear. 
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6.1 Role of Ficolins and MBL in Complement Activation 
Pathway 
There are three complement activation pathways: the classical pathway, the 
alternative pathway and the lectin pathway. Once the complement system is 
activated, opsonization of pathogens, chemotaxis and activation of leukocytes are 
promoted in innate immune response (Fujita et al., 2004). 
In classical pathway, pathogen is recognized by antibody. Complement Clq of 
the CI complex recognizes and binds to the Fc portion of the antibody. The serine 
protease, Clr and Cls in the CI complex were activated. Thus cleavage of C2, C3 
and C4 and the following lytic pathway were activated (James, 1982). 
In alternative pathway, activation of C3 can be initiated in the absence of 
antibody or lectin. It is a spontaneous and self-activated pathway with the 
involvement of complement factor B and factor D (Pangbum et al., 1981). 
In lectin pathway, three lectins including H-ficolin, L-ficolin and MBL 
recognize the carbohydrate on the surface of the pathogen and act as pattern 
recognition molecules. Mannose-binding lectin associated serine proteases (MASPs) 
are a group of proteases that activate the complement system. In plasma, MASPs 
exist as pro-enzyme in association with the collagen-like domains of H-ficolin 
(Matsushita et al., 2002), L-ficolin (Matsushita et al, 2000) or MBL (Matsushita et 
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al., 1998). Once the lectins bind to the surface of pathogen, they are activated to 
cleave the complement C2, C3 and C4. 
6.2 Structure of ficolins and MBL 
Lectins are a group of carbohydrate binding proteins which play an important 
role in innate immune response. The structures of the H-ficolin, L-ficolin and MBL 
account for their lectin activity. Ficolins and MBL are oligomers of structural 
subunits each composed of three identical polypeptide chains. Basically, each 
polypeptide chain is composed of four domains: a cysteine-rich amino terminal, a 
collagen-like domain, a neck region and a lectin domain. The lectin domain of 
ficolins was a fibrinogen-like domain and that of MBL was a C-type carbohydrate-
recognition domain. The collagen-like domain accounts for the covalent interaction 
between the three polypeptide chains of the subunit and also the covalent joining of 
several subunits into an oligomeric structure (Matsushita & Fujita, 2001). By 
electron microcopy, a hexameric form of H-ficolin (Sugimoto et al., 1998) and a 
tetrameric form of L-ficolin (Ohashi & Erickson, 1998) were observed; whereas 
MBL displays a range of oligomers from dimers to hexamers (Jensenius et al, 
2000). Homology between H-ficolin and L-ficolin is 48% overall, higher in the 
collagen-like domain (54%) and in the fibrinogen-like domain (53%), respectively 
(Sugimoto et al. 1998). The amino acid sequence alignment of H-ficolin and L-
ficolin is shown in Figure 6.1. 
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The serum concentration of H-ficolin in healthy blood donors is about 7-34 
/xg/ml (Yae et al., 1991; Krarup et al” 2005). H-ficolin mRNA expression is found in 
liver, lung and placenta (Akaiwa et al., 1999; Ota et al., 2004). In liver, H-ficolin is 
produced by bile duct epithelial cells and hepatocytes and secreted into the bile duct. 
In lung, H-ficolin is produced by ciliated bronchial epithelial cells and type II 
alveolar epithelial cells and secreted into the bronchus and alveolus (Akaiwa et al., 
1999). 
H-ficolin binds N-acetyl-glucosamine (GlcNAc), N-acetyl-galactosamine 
(GalNAc) and fucose but not mannose and lactose; and also lipopolysaccharide 
(LPS) of Salmonella typhimurium and Salmonella minnesota. The agglutination of 
erythrocytes coated with LPS from Salmonella typhimurium is inhibited by GlcNAc, 
GalNAc and fucose. It indicates that the binding of H-ficolin to LPS is mediated by 
its lectin activity (Sugimoto et al., 1998). H-ficolin also binds to PSA, a 
polysaccharide capsule structure purified from Aerococcus viridans (Tsujimura et 
al., 2001), which compose of glucose, mannose, GlcNAc and xylose. This calcium-
independent binding could not be inhibited by GalNAc, fucose and the constituent 
monosaccharides of PSA. Thus, the binding of PSA may differ from that of LPS. H-
ficolin was found to have an inhibitory effect on the growth of Aerococcus viridans 
that it binds Aerococcus viridans and activates complement activation (Tsujimura et 
al., 2002). Recently, H-ficolin was found to recognize apoptotic cells and activates 
complement via the lectin pathway. In vitro binding of H-ficolin to cClq receptor / 
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calreticulin suggests H-ficolin-bound apoptotic cells undergoes phagocytosis 
through cClp receptor without C3 and C5 activation. (Kuraya et al., 2005). 
6.2.2 L-ficolin 
L-ficolin is secreted by liver (Matsushita et al., 1996). The serum concentration 
of L-ficolin in healthy blood donors is 1.1 to 12.8 (median 3.7) ug/ml (Kilpatrick et 
al., 1999). L-ficolin exerts the lectin activity towards GlcNAc, but not mannose. The 
fibrinogen-like domain is responsible for its GlcNAc-binding activity (Le et al” 
1998). Other than the lectin activity, L-ficolin also binds elastin (Harumiya et al., 
1995) and corticosteroid (Edgar, 1995). However, its physiological significances of 
the interactions with elastin and corticosteroid are not clear. Recently, it was found 
that L-ficolin binds to lipoteichoic acid (LTA), a cell wall constituent of Gram-
positive bacteria, and subsequently activate the lectin pathway (Lynch et al., 2004). 
L-ficolin binds to LTA of Streptococcus agalactiae and plays important role in the 
opsonophagocytosis of Streptococcus agalactiae (Aoyagi et al., 2005). Also, like H-
ficolin, L-ficolin recognizes apoptotic cells and activates complement via the lectin 
pathway. (Kuraya et al., 2005). 
6.3 Immune Response and Pre-eclampsia 
Normal pregnancy itself is a state of systemic inflammation. Activation of 
leukocyte and complement were found to be enhanced in normal pregnancy relative 
to normal non-pregnant women. Pre-eclampsia is associated with a more extreme 
systemic inflammatory response than that occurs in normal pregnancy. The 
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inflammatory molecules that are already activated in normal pregnancy are more 
severely affected in pre-eclampsia. 
Number of monocytes and granulocytes increases from the first trimester 
onwards (Smarason et al., 1986). Circulating monocytes and granulocytes in whole 
blood show activated phenotypes (Shibuya et al, 1987; Smarason et al., 1986)， 
which include an increase in phagocytosis and an increase in expression of the 
endotoxin receptor. The third-trimester in normal pregnancy is characterized by 
remarkable activation of peripheral blood leukocytes, which is further increased in 
pre-eclampsia (Sacks et al , 1998). The leukocytes of normal pregnant women 
differed substantially and significantly from those of non-pregnant women by 
increased expressions of CD l ib, CD 14, and CD64 and also increased level of 
intracellular reactive oxygen species (Sacks et al., 1998). In pre-eclampsia, in 
addition to these changes, expression of L-selectins reduced and intracellular 
reactive oxygen species levels further increased (Sacks et al., 1998). 
Pregnancy induces activation of the classical complement pathway. C3 
concentration in the pregnant women was significantly raised but the C4 
concentration was reduced with a significant increase in C4d (Hopkinson & Powell， 
1992). C3a and C5a are the biologically active form of complement C3 and C5. C3a 
and C5a are formed when complement system is activated. Peptides C3a and C5a act 
as anaphylatoxin that bind to the surfaces of mast cells and basophils and cause the 
release of inflammatory mediators. The plasma C3a and C5a concentrations before 
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delivery were significantly higher in the pre-eclamptic women than in the normal 
pregnant women (Haeger et al., 1989). 
Pregnancy is a unique immune challenge. The mother has to suppress the 
rejection response to the fetus but maintain her resistance to infection. It is 
postulated that immune maladaptation is one of the causes of pre-eclampsia. The 
lower concentrations of plasma H-ficolin and L-ficolin in pregnancy complicated 
with pre-eclampsia require further evaluation and investigation. The roles of H-
ficolin and L-ficolin in the pathogenesis of pre-eclampsia and their relationship to 
immune responses in pregnancy complicated with pre-eclampsia need further 
investigation. 
The sample size used in this study was small. The validation group included 
only 45 normal pregnancies and 20 pre-eclampsia. The area under the ROC curve 
only gives us an estimation of the clinical value of using H-ficolin or L-ficolin in 
distinguishing between normal pregnancy and pre-eclampsia. L-ficolin may be a 
better test for distinguishing pre-eclampsia from normal pregnancy compared to H-
ficolin. Experiments with larger sample size shall be conducted to confirm the 
accuracy of using low concentrations of H-ficolin or L-ficolin as the markers of pre-
eclampsia for detection or even prediction. 
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Chapter 7 Conclusion 
From the comparative 2D-PAGE analysis, the quantities of two protein spots, 
Spot # 5204 and Spot #6210 were found to be significantly lower in plasma of pre-
eclamptic women compared to that of normal pregnant women. Spot # 5204 and 
Spot #6210 were then identified and confirmed to be H-ficolin and L-ficolin by 
mass spectrometry, respectively. The lower plasma concentrations of H-ficolin and 
L-ficolin in pre-eclamptic pregnancy were then confirmed by ELISA. The result of 
the ROC curve analysis indicates that L-ficolin may be a better biomarker for 
identifying pre-eclampsia from normal pregnancy. 
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Appendix 
a. Coomassie Brilliant Blue (CBB) Solution 
lOOmg Coomassie Brilliant Blue G-250 was dissolved in 50ml 95% ethanol. 100ml 
of 85% phosphoric acid was added. It was then topped up to 1 L with double 
distilled water. The solution was filtered through filter paper. The CBB solution was 
stored at 4C. The solution was warmed up at room temperature before use. 
b. H-ficolin Immunoassay 
H-ficolin levels in plasma samples were measured with microtiter plates (C8 
Maxisorp, Nunc, UK). Each well was coated with 100 /xl of 25 ug / /xl PSA, the 
polysaccharide from Aerococcus viridans, in coating buffer (sodium bicarbonate, 
NaHCOa, Sigma-aldrich, USA). It was blocked with 200 jLil blocking buffer (PBS, 
0.05 % Tween 20 and 0.2 % BSA, pH 7.4) at room temperature for 1 hour. 80 jul of 
H-ficolin standard / samples in blocking buffer was added and incubated at 37°C for 
1 hour. It was then washed with 200 washing buffer three times (PBS, 0.5% 
Tween 20). After that, 100 jul of mouse monoclonal anti-H-ficolin (clone 4H5, 
HyCult biotechnology b.v.) in blocking buffer was added and incubated at 37°C for 
1 hour. It was then washed with 200 /xl washing buffer three times. 100 jul of anti-
mouse Ig-peroxidase conjugate (Dako, Denmark) at 500-fold dilution in blocking 
buffer was applied and was incubated at 37°C for 1 hour. It was then washed with 
200 /xl washing buffer four times. 100 /xl of BM Blue substrate (Roche Diagnostic, 
Germany) was applied. The plate was shaken at room temperature for 30 min. 120 jul 
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of IM sulphuric acid (H2SO4) was added to stop the reaction. After shaking, 
absorbance was read at a wavelength of 450 nm with a reference wavelength of 690 
nm with a microplate reader (SPECTRA Rainbow, Tecan, Austria). 
c. L-ficolin Immunoassay 
L-ficolin levels in plasma samples were measured in microtiter plates (Immulon-
2HB, Dynex Technologies, UK). Each well was coated with 100 of 0.5 ugZ/xl 
monoclonal anti-L-ficolin (clone 2F5, Matsushita et al.) in coating buffer. It was 
blocked with 200 /xl blocking buffer at room temperature for 1 hour. 80 fi\ of L-
ficolin standard (Matsushita et al.) / samples in blocking buffer were added and was 
incubated at 37°C for 1 hour. It was then washed with 200 fA washing buffer. After 
that, 100 /il of rabbit polyclonal anti-L-ficolin (Matsushita et al.) in blocking buffer 
was added and incubated at 37°C for 1 hour. It was then washed with 200 fil washing 
buffer three times. 100 fxl of anti-Rabbit Ig-peroxidase conjugate (Roche Diagnostic, 
Germanys) at 500-fold dilution in blocking buffer was added and incubated at 37°C 
for 1 hour. It was then washed four times and 100 /xl of BM Blue substrate (Roche 
Diagnostic, Germany) was applied. The plate was shaken at room temperature for 30 
min. 120 /xl of IM sulphuric acid (IM H2SO4) was added to stop the reaction. After 
shaking, absorbance was read at a wavelength of 450 nm with a reference 
wavelength of 690 nm with a microplate reader (SPECTRA Rainbow, Tecan, 
Austria). 
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d. Mannose-Binding Lectin (MBL) Immunoassay 
MBL levels in plasma samples were measured in microtiter plates (Immulon-2HB, 
Dynex Technologies, UK). Each well was coated with 100 fil of 0.5 ug / fxl 
monoclonal anti-L-MBL (clone 3E7, Matsushita et al.) in coating buffer. It was 
blocked with 200 fi\ blocking buffer at room temperature for 1 hour. 80 /xl of MBL 
standard (Matsushita et al.) / samples in blocking buffer was added and incubated at 
37°C for 1 hour. It was then washed with 200 jul washing buffer three times. After 
that, 100 ix\ of DIG-labeled anti-MBL in blocking buffer was added and incubated at 
37°C for 1 hour. It was then washed with 200 fx\ washing buffer three times. 100 jul 
of anti-DIG-Ig-peroxidase conjugate (Roche Diagnostic, Germanys) at 500-fold 
dilution in blocking buffer was added and incubated at 37°C for 1 hour. It was then 
washed four times and 100 jul of BM Blue substrate (Roche Diagnostic, Germany) 
was applied. The plate was shaken at room temperature for 30 min. 120 jitl of IM 
sulphuric acid (IM H2SO4) was added to stop the reaction. After shaking, 
absorbance was read at a wavelength of 450 nm with a reference wavelength of 690 
nm with a microplate reader (SPECTRA Rainbow, Tecan，Austria). 
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